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INTRODUCTION
1. Definition of ODT: (1)
Generally, an ODT is a solid-dosage form that disintegrates and dissolves in the mouth
(either on or beneath the tongue or in the buccal cavity) without water within 60 seconds
or  less.  The  US  Food  and  Drug  Administration's  Center  for  Drug  Evaluation  and
Research developed the following definition for an ODT as a new dosage form in 1998:
"A  solid  dosage  form  containing  medicinal  substances,  which  disintegrates  rapidly,
usually within a matter of seconds, when placed upon the tongue" 
FDA issued  draft  guidance,  Guidance  for  Industry:  Orally  Disintegrating  Tablets,  to
recommend that,  in addition to the original  definition,  ODTs be considered solid oral
preparations that disintegrate rapidly in the oral cavity with an in vitro disintegration time
of  approximately  30  s  or  less,  when  based  on  the  United  States  Pharmacopoeia
disintegration test method or alternative. (2)
2. Market potential: (3)
Recent market studies indicate that more than half of the patient population prefers
ODT to other dosage forms, and most consumers would ask their doctors for
ODT (70%),  purchase  ODT (70%),  or  prefer  ODT to  regular  tablets  or
liquids (greater than 80%) (1) 
  Fig-1: Consumer’s preference of choosing ODT
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The global ODT market was estimated at $2.4 billion in 2004 and $3 billion in 2006,
according to Technology Catalysts International 
Recently,  increasing numbers of active pharmaceutical  ingredients (APIs)  have
been formulated into orally disintegrating dosage forms. The current market consists of
more  than  145  launched  products  (both  branded  and  generic)  for  92  molecules  (and
combinations), which is an increase of 10 molecules and more than 15 brands from 2004,
including prescription and over-the-counter (OTC) segments. ODT therapies for central
nervous system disorders (depression, mood disorders, migraine headaches, Alzheimer's
disease, insomnia, anxiety) still dominate the market, accounting for more than 40% of
the  market  value.  Gastrointestinal  (GI)  ODTs  increased  in  share  to  34%  by  value,
oncology  to  10%,  and  diabetes  to  7%.  In  2005–2006,  brand  companies  learned  that
patients perceived a faster onset of action with an ODT, and caregivers welcomed the
ease of administration of ODTs to patients who are reluctant  to comply with medical
orders or who became combatant when administered their medicine. These are likely the
contributing factors to the high growth in the ODT market (4)
 3. Advantages:
 Hard tablets, not fragile and easy to handle. 
 No specific packaging required, can be packaged in push through blisters. 
 Smooth mouth feel and pleasant taste. 
 Conventional  manufacturing  equipment,  not  difficult  to  transfer  to  final
production site. 
 Cost effective.
4. Types of ODTs:
For ease of comparison,  ODT may be categorized into two main groups:  lyophilized
formulations and loosely compressed tablets. Thin-film strips form a third category of
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solid, unit-dose, orally disintegrating products that aim to meet the same objectives of
ease of administration, patient convenience, and improved compliance. 
5. Challenges to Develop ODT:
    Taste: 
There are numerous pharmaceuticals that contain actives, which are bitter in taste.
With respect to OTC preparations, such as cough and cold syrups, the bitterness of the
preparation leads to lack of patient compliance. The problem of bitter and obnoxious taste
of drug in pediatric and geriatric  formulations is a challenge to the pharmacist in the
present  scenario.  In  order  to  ensure  patient  compliance  bitterness  masking  becomes
essential. Molecule interacts with taste receptor on the tongue to give bitter, sweet or
other taste sensation, when they dissolve in saliva. This sensation is the result of signal
transduction from the receptor organs for taste, commonly known as taste buds. These
taste buds contain very sensitive nerve endings, which produce and transmit electrical
impulses via the seventh, ninth and tenth cranial nerves to those areas of the brain, which
are devoted to the perception of taste. 
Two approaches are commonly utilized to overcome bad taste of the drug. The
first includes reduction of drug solubility in saliva,  where a balance between reduced
solubility and bioavailability must be achieved. Another approach is to alter the ability of
the drug to interact with taste receptor. An ideal taste masking process and formulation
should have the following properties.(5)
Techniques Employed for Taste Masking:
 Taste masking with Flavor enhancer:6
Flavoring  and  perfuming  agents  can  be  obtained  from either  natural  or  synthetic
sources.  Natural products include fruit juices, aromatic oils such as peppermint and
lemon  oils,  herbs,  spices  and  distilled  fractions  of  these.  They  are  available  as
concentrated  extracts,  alcoholic  or  aqueous solutions,  syrups  or  spirit.  Apart  from
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these conventional materials many compositions have been found to show effective
taste masking abilities with improved flavor such as alkaline earth oxide,  alkaline
earth  hydroxide  or  an  alkaline  hydroxide. Another  composition  includes
phosphorylated  amino  acid  such  as  phosphotyrosine,  phosphoserine,  and
phosphothreonine and mixtures thereof. Anethole effectively masked bitter taste as
well as the aftertaste of zinc. Clove oil and calcium carbonate, which has been found
to be particularly useful  to mask the unpalatable active in formulations which are
intended to be chewed or  dissolve in mouth prior to ingestion in solution.
 Taste masking with lipophilic vehicles: (7)
Lipids:  Oils,  surfactants,  polyalcohols,  and  lipids  can  be  used  for  taste
masking of bitter drugs. These substances act as taste masking agents by increasing
the  viscosity  in  the  mouth  and  coat  the  taste  buds.  Carnauba  wax,  magnesium
aluminium silicate, glyceryl  monostearate, gelatin, partially hydrogenated soyabean
oil, polyglycerine, fatty acid esters, chained triglycerides.
Lecithine  and  Lecithine  like  Substances:  Addition  of  sufficient  amount  of
lecithine and licithne like substances can completely mask the bitter taste of drugs.
Taste masked composition is prepared by dissolving or dispersing the bitter active
into a suitable organic solution followed by addition of lecithine to mask a blend and
finally  granulating  the  blend  with  other  excipients  to  prepare  a  taste  masked
grasnules.  Soyabean  lecithine,  homogenated  suspensions  of  phosphatidic  acid  and
beta lacto globuline from soyabean and milk respectively. 
 Taste masking by Coating with Hydrophilic vehicles: This is the simplest and
most  feasible  option  to  achieve  taste  masking.  Coating  prevents  the  interaction
between drug molecules and taste buds.
Carbohydrates: Coating the drugs with polymeric membrane can mask the taste
of  orally  administered  bitter  drugs.  Bitter  solid  drugs  are  formulated  in  an
organoleptically  acceptable  manner  by particle  coating with  a  mixture  of  a  water
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insoluble film forming polymer and second film forming polymer soluble at pH less
than five. Example is bitter solid drug such as pinaverium bromide.
Adsorption onto the polymeric carbohydrates is an effective for reducing the bitter
taste of active ingredients. Taste masking of ibuprofen has been successfully achieved
by using air-suspension coating techniques to form microcapsules, which comprise a
pharmaceutical  core  of  crystalline  ibuprofen  and  a  Methacrylic  acid  Co-polymer
[Eudragit] coating that chewable taste–masked characteristics. 
Chlorpheniramine maleate can be adsorbed onto Avicel PH 101 porous particles as an
aqueous solution containing 50 parts Chlorpheniramine maleate onto 3000 parts of
the polymeric material. The product obtained after adsorption was spray coated with
an aqueous solution containing xylitol to get the final coated product that was tasted
masked.  The  compressible  grade  formulation  of  xylitol  is  available  as
Xylitab.Triprolidine  hydrochloride  was  taste  masked  with  dispersion  coating  of
water-soluble polymer hydroxypropyl cellulose, plasticizing agent, and sweetener and
flavoring agent.
Pharmaceutical granules with bitter taste are coated with water- soluble polymers of
hydroxypropyl methyl cellulose and sugars such as sucrose and lactase to decrease
the  bitter  perception  at  the  time  of  administration  .The  bitter  taste  of  basic
pharmaceutical salts can be reduced or masked with weakly alkaline compounds of
good bioavailability
Proteins, Gelatins and Prolamines: Prolamine, an important protein component
can mask the taste of bitter active pharmaceuticals. Important prolamines used for
taste masking are Zein, Gliadin and Hardein. Advantages of using prolamines as taste
masking agents are as follow
a. Stability of tasrte masking effect during a long term storage period.
b. No interference with the immediate bioavailability of the drug.
c. In combination with the plasticizer, prolamine can controll the release of the
drug without any -harmful effect to taste masking.  
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Gelatins: Hydrolyzed gelatin has been found to provide an improvement in
taste  and  mouth  feel  when  incorporated  into  small  amounts  in  chewable  tablets
containing ingredients  for  taste  masking.  Water  insoluble gels  formed by Sodium
alginate in the presence of bivalent metals are also exploited for their taste masking
properties. Amiprilose HCl was taste masked by first coating the drug with calcium
gluconate followed by a coating of sodium alginate.
 Taste masking by drug-beta cyclodextrin inclusion complexation: (8)
Cyclodextrins are non-reducing cyclic glucose oligosaccharides resulting from the
cyclomaltodextrin  glucanotransferase  catalyzed  degradation  of  starch.  Their
structures have been reviewed. There are three common cyclodextrins with 6, 7 or 8
D-glucopyranonsyl residues (α-, β-, and γ-cyclodextrin respectively) linked by α-1,4
glycosidic bonds. The glucose residues have the  4C1 (chair) conformation. All three
cyclodextrins  have similar  structures  (that  is,  bond lengths  and orientations)  apart
from  the  structural  necessities  of  accommodating  a  different  number  of  glucose
residues. They present a bottomless bowl-shaped (truncated cone) molecule stiffened
by hydrogen bonding between the 3-OH and 2-OH groups around the outer rim. The
hydrogen bond strengths are α-cyclodextrin < β-cyclodextrin < γ-cyclodextrin. The
flexible 6-OH hydroxyl groups are also capable of forming linking hydrogen bonds
around the bottom rim but these are destabilized by dipolar effects, easily dissociated
in aqueous solution and not normally found in cyclodextrin crystals. The hydrogen
bonding is all 3-OH (donor) and 2-OH (acceptor) in α-cyclodextrin but flips between
this and all 3-OH (acceptor) and 2-OH (donor) in β- and γ-cyclodextrins.
Fig-2 Molecular structure of Cyclodextrin:
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The cavities have different diameters dependent on the number of glucose units
(empty diameters between anomeric oxygen atoms given in the diagram below). The
side rim depth (shown below in the diagrams) is the same for all three (at about 0.8
nm).Cyclodextrin rings are amphipathic with the wider rim displaying the 2- and 3-
OH groups and the narrower rim displaying 6-OH group on its flexible arm. These
hydrophilic  groups  are  on  the  outside  of  the  molecular  cavity  whereas  the  inner
surface is hydrophobic lined with the ether-like anomeric oxygen atoms and the C3-H
and C5-H hydrogen  atoms.  In  aqueous  solution,  this  hydrophobic  cavity  contains
about  3  (α-DC),  7  (β-DC)  or  9  (γ-DC) poorly  held (but  low entropy)  and  easily
displaceable  water  molecules.  This  water  in  the  cavities  has  low  density  as  the
cavities  are  large  enough  to  accommodate  several  more  molecules.  Thus,  the
otherwise  hydrophilic  cyclodextrin  molecules  may  bind  non-polar  suitably-sized
aliphatic and aromatic compounds such as aroma compounds and lipophilic drugs.
They may bind in 1:1, 2:1 and 1:2 ratios dependent on the molecules involved. The
binding  is  driven  by  the  enthalpic  and  entropic  gain  on  the  reduction  in  the
hydrophobe-aqueous surface and the release of water molecules from the cavity to the
bulk phase. Such binding also allows cyclodextrins to be used to increase the water
solubility of normally hydrophobic compounds or minimize undesirable properties
such as odor or taste in certain food additives.
Fig-3: General and 3-D structures of 3 types of cyclodextrins:
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Table-1: Comparison of properties of three types of cyclodextrins.
Properties of cyclodextrins
Cyclodextrin Mass Outer
diameter,
(nm
Cavity diameter (nm) Solubility,
g/kg H2O
Hydrate H2O
Inner rim Outer rim
cavity external
α,(glucose)6 972 1.52 0.45 0.53 129.5 2.0 4.4
β,(glucose)7 1134 1.66 0.60 0.65 18.4 6.0 3.6
γ,(glucose)8 1296 1.77 0.75 0.85 249.2 8.8 5.4
Mechanism of Complex formation:  (9)  Crystalline beta cyclodextrin contains 13-14%
(w/w) water. Half of this water is so called crystal water and other half is inclusion water.
The crystal water is located and bound between the adjacent CD molecules, while the
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inclusion water is included into the hydrophobic cavity of the CD. The mechanism of
complex  formation  is  always  the  substitution  of  these  water  molecules  by  a  more
appropriate, more hydrophobic guest molecule, which forms a more stable complex with
the CD.
Method of complex formation:
 Kneading:  Weigh required quantity of drug and CD and take in a mortar. Start
kneading with pestle with slowly addition of water for some time and kept it for
drying  at  45˚C.  The  dried  complex  was  kept  in  a  well  closed  container  after
passing through mesh# 60.
 Co-Crystallization: Required amount of drug is dissolved in required amount of
warm or cold solvent and mixed with suspension of β CD in water. This mixture
is stirred and heated until complete dissolution of the β CD. After standing for
sufficient time a precipitation of a white microcrystalline complex occurred that
can be isolated by filtration.
 Spray drying: Mix the drug and CD in appropriate ratio and dissolve the mixture
in required amount of water and heat the aqueous mixture to 80˚C till complete
dissolution then spray dried to a non bitter powder.
Taste masking by ion-exchange resins: (10)
Ion  exchange  resin  may be  defined  as  high  molecular  weight  water  insoluble
polymers  containing  fixed positively or  negatively charged  functional  groups  in  their
matrix which have an affinity for oppositely charged counter ions. Since the majority of
drugs posses an ionic site in their molecules the charge of the resin provides a means to
loosely attach such drugs to insoluble polymers. The principle property of these resins is
their capacity to exchange bound or insoluble ions with those in solution. Soluble ions
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may be removed from solution through exchange with the counter ions absorbed on the
resin. These exchanges are equilibrium reaction in which the extent of exchange will be
governed by the relative affinity of the resin for particular ions. 
Physical properties and chemistry of IER: (11) In general  IER consists of spherical
beads of approximately 0.5-1.2 mm in diameter.  The most common type is an
opaque yellow in color, although other colors are also reported. The construction
of each spherical particle of IER is similar to that of a homogeneous gel.  The
shrinkage or expansion of the spherical volume that take place is based on the
ionic environment in which the IER is present. The insolubility of IER depends
upon the nature of the counter ion and the extent of cross linking of the basic
skeleton of IER and hence careful consideration should be given to the selection
of IER. Commercially available IER swell  in water  to 2-3 times their original
weight. Despite strong swelling, the chemical stability remains satisfactory.
Chemically IER are made up of two components: a structural component consisting of
the  polymer  matrix,  and  a  functional  component  to  which  the  counter  ion  in
bound. The structural component of IER consists of a stable acrylic polymer of
styrene-  divinylbenzene copolymer,  whereas   the functional component can be
acidic (sulfonic and carboxylic) or basic (amine)
Types of Ion Exchange Resins: (12)
Cation exchangers (Anionic resin):
Cation-exchange  resin  is  prepared  by  the  copolymerization  of  styrene  and  divinyl
benzene and have sulphonic acid groups (-SO3H) introduced into most of benzene rings.
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The functional groups of these resins undergo reaction (exchange) with the cations in the
surrounding medium. 
The mechanism of cation exchange can be depicted by the following reaction. 
Resin- - ex+ + C+ →Resin- - C+ +ex+ 
Where, Resin- indicates polymer with SO3- sites available for bonding with exchangeable
cation (ex+) and C+ indicates cation in the surrounding solution getting exchanged. Cation
exchangers  are  again  subdivided  into  inorganic  and  organic.  Inorganic  includes  two
classes i.e. Natural (e.g. modified green sand, clays) and Synthetic (e.g. zeolite). Organic
ion  exchangers  are  subdivided  into  3  groups.  Natural  (peat,  ignite),  Semisynthetic
(Sephadex ion exchangers, zeocrab), Synthetic (acrylic acid copolymers)
Anion exchangers (Cationic resin)
These are the polyelectrolytes  undergoing reaction with the anions of the surrounding
solutions. They are prepared by first chlor-meythylating the benzene rings of styrene-
divinylbenzene copolymer to attach CH2Cl groups and then causing these to react with
tertiary amine such as triethylamine. The mechanism of anion exchange can be depicted
by the following reaction. 
Resin+ - ex - + A- → Resin+ - A- + ex- (2) 
Where, Resin+  indicates polymer with N+ sites available for bonding with exchangeable
anion (ex-) and A- indicates cation in the surrounding solution getting exchanged.
Advantages of resins
 Resins being polyelectrolyte  have extensive binding sites  leading to very high
drug loading ability.
 They are chemically inert and free from local and systemic side effects.
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 Because of ion exchange ability, they have been used in taste masking, modified
release and therapeutic applications.
 All conventional  solid,  semisolid and liquid dosage  forms can be prepared by
using resins. 
 They have been used in selective separation/recovery of  pharmaceuticals  from
mixtures.
 Being stable to all sterilization means, can be formulated in to all sterile dosage
forms. 
Types of Drug Resin Interactions:
Fig-4: Electrostatic and hydrophobic interaction seen in drug resin complex.
 
The  chemistry  of  resinate  is  such  that  the  drug  retains  its  characteristics  but  is
immobilized on a solid support.  The interactions  between the IER and drug although
primarily chemical  in nature,  are also partially a result  of physical  adsorption.  These
interactions are commonly referred to as adsorption on IER. The IE process therefore is
generally regarded as a double –decomposition process, in which the IER used are able to
provide the type of ion required to replace the one that is adsorbed from the solution the
ion of the IER,   which can be exchanged for a drug counterpart, is called a counter ion.
The affinity of counter and drug ions towards the IER is competitive.
Factors Affecting Resin Performance:
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 Degree of cross linking: Less degree of cross linking results more porous resin
which exhibit higher extent of swelling due to hydration. Whereas, if it is less
cross linked, then it has less swelling. Because of this, the drug loading ability of
less cross linked resin is high than more cross linked. But, the drug release from
former is rapid and sustained from latter ones. 
 Particle  size:  The smaller  resin beads  offering more surface area have shown
rapid  exchange  of  ions  but  shorter  diffusion  path  length.  Whereas,  the  larger
beads, have more diffusion path length leading to sustained release. 
 pH: If the pH of surrounding medium is acidic then it promotes dissociation of
basic drugs leading to formation of more ionic species available for drug loading.
And towards alkaline pH, the dissociation of acidic drugs will be promoted. With
increase in dissociation, the complexation efficiency gets improved. With increase
in pH, protonated fraction of cationic drug decreases and hence interaction with
resin  or  loading  with  beads  decreases.  It  has  been  observed  that,  release  of
phenylpropanolamine was rapid in eluants with low pH. 
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 Size  of  exchanging  ion:  It  has  been  observed  that,  with  increase  in  size  of
exchanging ion, slower was drug loading, and less diffusion rate followed by slow
release. 
 Selectivity of counter ion: The ions with low selectivity for resin such as –H+ get
replaced faster by cationic drugs resulting in higher loading. 
 Mixing time:  With increase in the mixing time, the swelling of resin goes on
increasing and ultimately drug loading. In the initial phases, the drug loading seen
was more and later on it was less. It has been reported that, complete drug loading
can be achieved in 1-2 hour only by batch process. 
 Effect  of  temperature: For  certain  resins  the  effect  of  temperature  on  drug
loading has been reported. High temperature may also cause swelling of resin.
Cation exchange resin does not get significantly affected by temperature changes
unlike anion exchangers. 
 pKa:  The pKa value of the resin is having significant  influence on the rate at
which the drug is  released from the resinate in the gastric  fluids. The anionic
resins  having  sulfonic,  phosphoric  or  carboxylic  acid  exchange  groups  have
approximate  pKa  values  of  <1-6.  And,  cationic  resins  containing  quaternary,
tertiary,  or secondary ammonium groups have pKa values  of  5-13 and greater
than 13.The pKa of drug also decides the extent of dissociation and complexation
with the resin. 
 Ion  exchange  capacity:  The  IE  capacity  of  strong  ion  exchange  resin  is
determined  as  meq/gm  by  evaluating  the  number  of  moles  of  Na+  which  are
absorbed by 1 gm of the dry resin in the hydrogen form. Similarly the IE capacity
of a strong basic AER is evaluated by measuring the amount of Cl-   taken up by 1
gm of the dry resin in the hydroxide form.
Preparation of Resinate: 
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 Batch  technique:  In  this  processs  a  specific  quantity  of  the  granular  IER  is
agitated with drug solution until the equilibrium is achieved.
 Column technique:  A concentrated solution of drug is passed through the IER
packed  column  until  the  effluent  concentration  is  the  same  as  the  eluent
concentration.
Miscellaneous taste Masking Approaches: (7)
 By effervescent Agent:  Taste masking of bitter actives for oral delivery can be
achieved by adding required quantity of effervescent agents in the formulation. In
addition to the effervescent agents taste masking generator of carbon dioxide and
a  taste  bud  desensitizing  agent  is  also  incorporated.  Recently  taste  masked
formulation of Fentanyl and Prochlorperazine with effervescent agents have been
developed.
 Rheological  Modifications:  Rheological  modifiers  play  an  important  role  for
taste  masking  of  pharmaceutical  liquid  preparation.  These  agents  prevent  the
diffusion of bitter active substances from the saliva to the taste buds. Examples
include  xanthan  gum,  microcrystalline  cellulose,  PEG,  PPG  with  polyvinyl
pyrollidone,  gum  arabic,  gelatin,  sodium  alginate,  maltitol.  Drugs  like
Acetaminophen,  Phenobarbital,  Tannic  acid  and  Mitrazapine  have  been
successfully taste masked by this process.
 Salt preparation: Adding alkaline metal bicarbonate such as sodium bicarbonate
masks the unpleasant taste of drugs. Caffeine may be masked by formulating it as
a  carbonated  oral  solid  preparation  using  sodium bicarbonate,  ascorbic  acids,
citric acid and tartaric acid. 
 Solid Dispersion Systems: Solid dispersion has been defined as dispersion of one
or more active ingredients in an inert carrier or matrix at solid state prepared by
melting (fusion) solvent or melting solvent method. Solid dispersion is also called
as co precipitates for those preparation obtained by solvent method such as co
precipitates  of  sulphathiazale  and  povidone. Solid  dispersions  using  insoluble
matrices or bland matrices may be used to mask the bitter taste of drugs. Also
15
using them as absorbates on various carriers may increase the stability of certain
drugs.
2. Mouth feel: (13) 
Mouth feel is critical and patients should receive a product that feels pleasant.
Any large particles from the disintegrating tablet that are insoluble or slowly soluble in
saliva would lead to an unpleasant gritty feeling. This can be overcome by keeping the
majority of the particles below the detectable size limit. Effervescence can be added to
aid disintegration and improve mouth feel by reducing the "dryness" of a product.
3. Disintegration Time:
The time for an ODT to disintegrate in the oral cavity also varies by product and
the method of manufacturing. Compressed tablets will typically take slightly longer to
disintegrate  than  freeze-dried  wafers  due  to  a  different  bonding  mechanism  and
differences  in  porosity  between  the  two  dosage  forms.  Compression-molded  tablets
would be expected to have disintegration times that are similar to compressed tablets. The
method  used  to  determine  disintegration  time  is  also  critical,  and  the  disintegration
method stated in the United States Pharmacopoeia (USP) for conventional "hard" tablets
may not be appropriate. USP 26 states that method is: "provided to determine compliance
with the limits on disintegration stated in the individual monographs except where the
label  states  that  the  tablets  or  capsules  are  intended  for  use  as  troches,  or  are  to  be
chewed."
The lack of an appropriate disintegration test for ODT products results in USP
method being the only official method available. However, this test is quite aggressive
for ODT products and results in disintegration times as short as a few seconds. Several
companies have developed their own internal, more discriminating method to measure
disintegration  times  of  these  dosage  forms.  In  vivo disintegration  times  will  vary
tremendously depending on how the patient processes the dosage form. A patient that
actively moves the product around the oral cavity with the tongue will experience a faster
disintegration time than one who allows the product to disintegrate without any additional
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encouragement.  It  is important  to note that even though this type of dosage form has
inherent  patient-to-patient  disintegration  time variability,  an approved  ODT must still
meet the typical requirements for bioequivalence, independent of disintegration time.
4 .Dissolution Studies:
For  bioequivalent  formulation,  USP  monographs  dissolution  conditions  should  be
followed  in  addition  0.1N  hydrochloric  acid,  and  pH4.5  and  6.8  buffers  should  be
evaluated for orally disintegrating tablets. The USPII (paddle speed of 50rpm) apparatus
is most suitable for ODT. For tablet weight one gram or more then paddle speed to be
increased.  The  taste-masking  plays  major  role  in  dissolution  method  development.
Several companies are developing their internal standards to get more discrimination of
the product performance.  
5. Bioequivalace: (13)
Creating an  ODT form of  an existing immediate-release  product  means that  the  two
formulations must be bioequivalent. This can be challenging, especially if the method of
taste masking retards the dissolution rate of the active ingredient after disintegration of
the  ODT.  Contrary  to  some patients'  perceptions,  shorter  disintegration  times  do not
necessarily mean quicker absorption. Typically, depending on the regulatory strategy, the
pharmaceutical company wants to see drug dissolution rates for an ODT that are similar
to  the  immediate-release  innovator,  at  least  until  an  IVIVC  can  be  made.  ODT
formulations are designed to disintegrate  quicker  than their counterparts,  and this can
lead to difficulties finding a discriminating dissolution test method. If, for example, 90%
of the drug is released in 5 minutes, any small batch-to-batch changes may be difficult to
identify.
Review of Literature
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1. M.E. Bhanoji Rao, K.E.V. Nagoji, G. Chandrasekhar prepared and evaluated
dispersible tablets of nimesulide using primojel as dispersing agent with starch,
lactose  and  dicalcium  phosphate  as  diluent.  The  formulation  with  starch  and
lactose as diluent showed fast and rapid dissolution when compared to that of
commertial  tablets  where  as  formulatons  with  dicalcium phosphate  as  diluent
showed less dissolution rate. (25)
2.  Sarath Chandar, Gary Telfer Norman, Kalyan S. Nuguru, Arun F. Amin
disclosed a co-processed carbohydrate system as a quick- dissolve matrix for solid
dosage  forms  in  US  patent  no  US  7,118,765  B2.  They  invented  a  directly
compressible quick dissolve matrix prepared by spray dried Mannitol and sorbitol
followed  by  addition  of  superdisintegrants  for  achieving  invivo  disintegration
time of less than 60 seconds and lubricant for good flow property. (24)
3. Kiran Bhise,Shafi  Shaikh,and Divyakumar  Bora masked  the  bitter  taste  of
Diphenhydramine Hydrochloride (DPH) using cation exchange resins Indion 234
and  Tulsion  343  .The  drug  resin  complexes  (DRC)  were  prepared  by  batch
process by taking drug: resin ratios 1:1, 1:2, and 1:3. Effervescent and dispersible
tablets  were  developed  from optimum drug:  resin  ratios  of  1:2  and  1:1.  The
formulations were evaluated for uniformity of dispersion, disintegration time, and
in  vitro  dissolution..  The  drug  release  of  95%  in  15  min  was  observed  for
effervescent and dispersible tablets.(26)
4. A. S Mundada, D.R Meshram, H. B Banbale, M. R Bhalekar,  J.  G Avari
masked the bitter taste of roxithromycin by complexation technique. Weak cation
exchange resins Indion 214 and Amberlite IRP64, polymer carbopol 934P were
used  in  formulation  of  complexes  with  the  drug.  The  loading  process  was
optimized for the pH of loading solution and resin or polymer:drug ratio.  The
complexes were evaluated for bulk density, angle of repose, taste masking, and in
vitro drug  release.  In  vitro drug  release  studies  showed  more  than  80% drug
release  from the  optimized  formulation  within  30  min.  Amberlite  IRP64  was
found to be better complexing agent for masking the bitter taste of roxithromycin.
(27)
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5. Shagufta Khan, Prashant Kataria, Premchand Nakhat, and Pramod Yeole
performed  taste  masking  by  complexing  ondansetron  HCl  with  aminoalkyl
methacrylate  copolymer  (Eudragit  EPO) in different  ratios by the precipitation
merethod. Polyplasdone XL-10 7% wt/wt gave the minimum disintegration time.
Tablets containing spray-dried mannitol and microcrystalline cellulose in the ratio
1:1 and 7% wt/wt Polyplasdone XL-10 showed faster disintegration, within 12.5
seconds,  than  the  marketed  tablet  (112  seconds).Tablets  revealed  rapid  drug
release (t90, 60 seconds) in SGF compared with marketed formulation (t90,  240
seconds;).  Thus,  results  conclusively demonstrated  successful  masking of  taste
and rapid disintegration of the formulated tablets in the oral cavity. (28)
6. Punit P. Shah and Rajashree C. Mashru masked the intensely bitter taste of
amotidineArtemether  and  formulated  a  rapid-disintegrating  tablet  of  the  taste-
masked  drug.  Taste  masking  was  done  by solid  dispersion  with  mono amino
glycyrrhyzinate pentahydrate by solvent evaporation method. To characterize and
formulate  taste  masked  rapid  disintegrating  tablets  of  ARM,  the  1:1M  solid
dispersion was selected based on bitterness score.  In  vitro  drug release studies
were  performed  for  RDTs  at  pH  1.2  and  6.8.  RDTs  prepared  using  solid
dispersion, (RDT3), showed faster disintegration (within 28 s) and complete bitter
taste masking of ARM. In addition, RDT3 exhibited better dissolution profile at
both pH 1.2 and 6.8, than RDTs prepared from pure ARM (RDT5).(29)
7. V.  Ananda,  R.  Kandarapub,  S.  Gargc  prepared  taste-masked  orally
disintegrating  tablets  of  Prednisolone by incorporation  of  microspheres  by the
solvent  evaporation method using acetone  as solvent  for  pH-sensitive polymer
and light liquid paraffin as the encapsulating medium. Taste evaluation studies
confirmed that microspheres of PDL having a drug to polymer ratio of 1: 10 are
tasteless and these were further used for formulation into ODTs. Compression of
microspheres resulted in breaking of a fraction of the microspheres but this did
not adversely affect the taste. Effective taste-masking was achieved for PDL using
the technique of microencapsulation and ODTs of acceptable characteristics were
obtained by disintegrants addition and direct compression.(30)
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8. Jianchen  Xua,  Li  Li  Bovetb,  Kang  Zhao  produced  microspheres  by  spray
drying  a  mixture  of  Famotidine  with  taste  masking  material  and  form orally
disintegrating  tablets.  Results  from  an  evaluation  by  a  panel  of  six  human
volunteers demonstrated that the orally disintegrating tablets with taste masking
microspheres improved the taste significantly.The taste masking potential of the
microspheres  incorporated  in  ODTs  was  evaluated  by  dissolution  test  of
microsphere particles and tablets, in vivo rat study, and taste masking test as well
as the disintegration time in the buccal cavity with a panel of human volunteers.
The ODTs can disintegrate in the buccal cavity within 30 s with improved taste.
The  microspheres  neither  decrease  the bioavailability  nor  delay the release  of
famotidine significantly.(31)
9. Sambhaji Pisal, Rana Zainnuddin, Pradeep Nalawade, Kakasaheb Mahadik
and Shivajirao  Kadam formulated  tasteless  complexes  of  ciprofloxacin  with
Indion 234 and evaluated molecular properties of drug complexes. The efficient
drug loading was evident in batch process using activated Indion 234 with a drug-
resin ratio of 1:1.3. Drug complexation enhanced with pH from 1.2 to 6, while
temperature  did  not  affect  the  complexation  process.  Infrared  spectroscopy
revealed complexation of –NH (drug) with Indion 234. DRC are amorphous in
nature. Drug release from DRC in salivary pH was insufficient to impart bitter
taste.  Volunteers  rated the complex  as  tasteless and agreeable.  Complete drug
release was observed at gastric pH in 2 hours. (32) 
10. Hiroyuki  Suzuki  ,  Hiraku  Onishi,  Yuri  Takahashi  ,  Masanori  Iwata,
Yoshiharu  Machida  developed  taste  masked  Acetaminophen  oral  chewable
tablet using some matrix bases like Corn starch/lactose, cacao butter and hard fat
(Witepsol H-15) and corrigents like sucrose, cocoa powder and commercial bitter
masking powder  mixture  made from lecithin  (Benecoat  BMI-40).  The  present
studies  revealed  that  when  the  acetaminophen  chewable  tablets  are  made  of
various formulations, Witepsol H-15 containing Benecoat BMI-40 (5%)/sucrose
(1 or 5%), or cocoa powder (1%)/sucrose (1%), or sucrose (5%) alone could mask
bitter taste of the drug most excellently. Such masking effect appeared to be fairly
related to lipophilic characteristics of the additives. Further, the tablets obtained
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with the above formulations showed a good drug release in  vitro irrespective of
chewing.  Thus,  these  tablets  are  proposed  to  be  available  as  chewable
acetaminophen tablets with inhibited bitter taste.  However,  Witepsol H-15 can
cause an unpleasant feeling in the oral cavity because of its melting characteristics
in the mouth, as expressed by volunteers. (33)
11. C Mallikarjuna  Setty,  D.V.K Prasad,  V.R.M Gupta,  B.  Sa developed  fast
dispersible  Aceclofenac  tablets  and  studied  the  effect  of  functionality  of
superdisintegrants.  Aceclofenac fast-dispersible tablets were prepared  by direct
compression  method.  Effect  of  superdisintegrants  (such  as,  croscarmellose
sodium,  sodium  starch  glycolate  and  crospovidone)  on  wetting  time,
disintegration  time,  drug content,  in  vitro release  and  stability  parameters  has
been  studied.  Disintegration  time  and  dissolution  parameters  (t50% and  t80%)
decreased  with  increase  in  the  level  of  croscarmellose  sodium.  Where  as,
disintegration time and dissolution parameters increased with increase in the level
of sodium starch glycolate in tablets. However, the disintegration time values did
not reflect in the dissolution parameter values of crospovidone tablets and release
was dependent on the aggregate size in the dissolution medium. Stability studies
indicated  that  tablets  containing  superdisintegrants  were  sensitive  to  high
humidity  conditions.  It  is  concluded  that  fast-dispersible  Aceclofenac  tablets
could be prepared by direct compression using superdisintegrants. (34)
12. J. Balasubramaniam, K. Bindu, V. U. Rao, D. Ray, R. Haldar and A. W.
Brzeczko studied the  effects  of  selected  superdisintegrants  on  the  dissolution
behavior of several cationic drugs with varying water solubility. All formulations
were  made with  fixed disintegrant  concentration  and  equal  drug  load  using  a
model  formulation.  Tablets  were  made  by  direct  compression  and  were
compressed to equal hardness. Dissolution studies were carried out in dissolution
media specified in the compendium (USP) or in media recommended by the U.S.
Food and Drug Administration (FDA) for the respective actives.  The effect  of
media pH on the dissolution of drugs was also evaluated. The use of crospovidone
significantly  improved  the  dissolution  of  the  cationic  drugs  in  the  model
formulation  when  compared  with  the  other  superdisintegrants  studied.
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Crospovidone  can  be  effectively  used  as  a  tablet  disintegrant  to  improve  the
dissolution of either soluble or poorly soluble cationic drugs. (35)
13. Garala Kevin C., Ekshinge Vinit B., Jarag Ravindra J. and Shinde Anil J.
made an attempt had been made to prepare fast disintegrating tablets of the drug
using different super disintegrants following wet granulation method. The sodium
starch glycolate, cross carmellose sodium and pregelatinized starch (Starch 1500)
were used in different concentrations according to the simplex lattice design as
the  super  disintegrants.  The  tablets  were  evaluated  for  diameter,  thickness,
hardness,  friability,  weight  variation,  wetting  time,  percentage  of  water
absorption, disintegration time and in vitro dissolution studies. The disintegration
time  of  all  formulation  showed  less  than  89  seconds.  Formulation  containing
equal  amount  of  Cross  carmellose  sodium  and  pregelatinized  starch  showed
fastest  disintegration  than  other  formulations  containing  Starch  1500,  cross
carmellose sodium and sodium starch glycolate  in various  proportions and the
percentage drug release was 99.5 within 10 minutes.(36)
14. S Furtado,  R Deveswaran,  S  Bharath,  BV Basavaraj,  S  Abraham and V
Madhavan investigated the effect of camphor as a subliming agent on the mouth
dissolving  property  of  famotidine  tablets.  Orodispersible  tablets  of  famotidine
were prepared using camphor as subliming agent and sodium starch glycollate
together  with  crosscarmellose  sodium  as  superdisintegrants.  The  formulations
were  evaluatedtidine  for  weight  variation,  hardness,  friability,  drug  content,
wetting  time,  in  vitro  and  in-vivo  dispersion,  mouth  feel  and  in  vitro
dissolution.All the formulations showed low weight variation with dispersion time
less than 30 seconds and rapid in vitro dissolution. The results revealed that the
tablets  containing  subliming  agent  had  a  good  dissolution  profile.  The  drug
content  of all  the formulations  was within the acceptable  limits of the United
States Pharmacopoeia XXVII.  The optimized formulation showed good release
profile with maximum drug being released at all time intervals.(37)
15. Formulation  and  characterization  of  fast-dissolving  tablet  of  promethazine
theoclate. Shailesh Sharma, GD Gupta prepared fast-dissolving tablets (FDT) of
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promethazine  theoclate  by  direct-compression  method  after  incorporating
superdisintegrants Ac-Di-Sol, Sodium Starch Glycolate (SSG), and Crospovidone
in  different  concentrations.  Nine  formulations  having  superdisintegrants  at
different concentration levels were prepared to assess their efficiency and critical
concentration  level.  Different  types  of  evaluation  parameters  for  tablets  were
used.  Tablets containing Ac-  Di- Sol showed superior  organoleptic  properties,
along with  excellent  in vitro and  in vivo dispersion  time and drug release,  as
compared to other formulations. (38)
16. Shirsand  SB,  Para  MS,  Swamy  PV,  Nagendra  Kumar  D,  Sunil  F
designed  fast  disintegrating  tablets  of  Prochlorperazine  maleat  using
camphor  as  the  subliming  agent  (up  to  30%  w/w),  crospovidone  and
croscarmellose  sodium  (2-8%  w/w)  was  used  as  superdisintegrant.  The
prepared formulations were further evaluated for hardness, friability, drug
content  uniformity,  in  vitro  dispersion  time,  wetting  time  and  water
absorption ratio. Based on in vitro dispersion time (approximately 10-15 s),
two promising formulations (one from each super-disintegrant) were tested
for in vitro drug release pattern in pH 6.8 phosphate buffer. Among the two
promising  formulations,  the  formulation  (SCP3)  containing  8%  w/w  of
crospovidone and 30% w/w camphor as the subliming agent emerged as the
overall best formulation (t50%=6 m) based on drug release characteristics in
pH  6.8  phosphate  buffer  compared  to  commercial  conventional  tablet
formulation (t50%=17.4 m). (39)
17. Uday S. Rangole, P. S. Kawtikwar and D. M. Sakarkar carried out their research on
formulation  and  in  vitro  evaluation  of  rapidly  disintegrating  tablets  by  direct
compression  technology  using  Hydrochlorothiazide  as  a  model  drug.  Fast
disintegrating  tablet  of  hydrochlorothiazide  was  formulated  using  different
concentration (2%, 3%, 4% and 5%) of superdisintegrants like Croscarmellose
sodium and Crospovidone. Disintegration time and drug release were taken as the
basis to optimize the rapidly disintegrating tablet. Prepared tablets were evaluated
for  thickness,  hardness,  friability,  uniformity  of  weight,  disintegration  time,
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wetting time and dissolution study.  Crospovidone in the concentration of 4 %
gives fasted disintegration in 16 sec. and shows 100% drug release within 14 min.
is selected as the optimized formulation. (40)
18. Na  Zhao,and  Larry  L.  Augsburger investigated  the  influence  of  swelling
capacity  of  superdisintegrants  in  different  pH  media  on  the  dissolution  of
Hydrochlorothiazide From Directly Compressed Tablets. Significant reductions in
the rate and extent of water uptake and swelling were observed for both sodium
starch glycolate (Primojel) and croscarmellose sodium (Ac-Di-Sol) in an acidic
medium  (0.1  N  HCl)  but  not  for  crospovidone  NF  (Polyplasdone  XL10),  a
nonionic polymer.  When Primojel and Ac-Di- Sol were incorporated in model
formulations, a significant increase in tablet disintegration time was observed for
slowly  disintegrating  tablets  (lactose-based  tablets)  but  not  for  the  rapidly
disintegrating tablets (dicalcium phosphate-based tablets). The dissolution rate of
the model drug, hydrochlorothiazide, was found highly dependent on both tablet
disintegration  efficiency  and  the  solubility  of  base  material(s)  in  the  testing
medium. (41)
19. R.  Doijad,  F.  Manvi  &  K.  D.  Khalandar formulated  Granisetron  mouth
dissolving tablets, by incorporation of super disintegrants in the formulation and
evaluated  overall  efficiency  of  them.  The  tablets  were  prepared  by  wet
granulation method. PVP K-32 in isopropyl alcohol is used as binder. Then the
granules were compressed on a Cadmach single stroke punch machine. All the
four formulation showed flat,  smooth tablets with  10 mm diameter.  Hardness,
friability,  weight  variation and drug content  were within limits.  Disintegration
time of all formulations was within 60s. As the formulations F1, F2, F3 contained
super disintegrants, they showed faster disintegration time, than the formulation
F4. Overall  the lag time for disintegration of tablet is  reduced,  thereby aiding
pregastric  absorption of granisetron.  Hence first  pass metabolism is minimized
and oral bioavailability may be enhanced. (42)
20. Jashanjit Singh and Rajmeet Singh studied the formulation and optimization of
orodispersible  tablets  of  meloxicam  using  a  22 factorial  design  for  enhanced
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bioavailability.  The  tablets  were  made  by  non-aqueous  wet  granulation  using
crospovidone and  mannitol.  A 22 factorial  design  was  used  to  investigate  the
amount  of  crospovidone  and  taste  masking,  soothening  hydrophilic  agent
(Mannitol),  as  independent  variables,  and  disintegration  time  as  dependent
response. Formulated orodispersible tablets were evaluated for weight variation,
friability, disintegration time, drug content, wetting time, water absorption ratio
and  in  vitro  drug  release.  The  results  showed  that  the  presence  of  a
superdisintegrant and Mannitol is desirable for orodispersion. All the formulations
satisfied the limits of orodispersion with a dispersion time of less than 60 sec. For
example,  formulation  F4  showed  a  disintegration  time  of  32.1  sec,  crushing
strength of 4.93 kg/cm2, drug content of 98.5% and fast drug release rate of 99.5%
within 30 min, as compared with the conventional tablet (49.5%). (43)
21. Na  Zhao  and  Larry  L.  Augsburger aimed  to  compare  the  disintegration
efficiency,  and  to  develop  a  discriminating  test  model  for  the  3  classes  of
superdisintegrants represented by Ac-Di-Sol, Primojel, and Polyplasdone XL10.
Using  a  digital  video  camera  to  examine  the  disintegration  process  of  tablets
containing the same wt/wt percentage concentration of the disintegrants, Ac-Di-
Sol was found to disintegrate  tablets rapidly into apparently primary particles;
Primojel  also  apparently  disintegrated  tablets  into  primary  particles  but  more
slowly; Polyplasdone XL10 disintegrated tablets rapidly but into larger masses of
aggregated  particles.  The  differences  in  the  size  distribution  generated  in  the
disintegrated  tablets  likely  contribute  to  the  drug  dissolution  rate  differences
found for aspirin tablets with similar disintegration rates. The aspirin tablet matrix
is proposed as a model formulation for  disintegrant  efficiency comparison and
performance consistency testing for quality control purposes. (44)
22. Xiaorong Hea,  Michael  R.  Barone ,  Patrick  J.  Marsac  ,  David C.  Sperry
developed a rapidly dispersing tablet of a poorly wettable compound and carried
out formulation DOE and mechanistic study of effect of formulation excipients on
wetting of celecoxib. A dispersibility method was developed to study the effects
of  formulation  excipients  and  processing  methods  on  wetting  of  celecoxib.
Results show that wet granulation facilitates better drug dispersion than does dry
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granulation or direct compression. Polyplasdone XL as a disintegrant results in
better celecoxib dispersibility than sodium starch glycolate. The binder Kollidon
30 leads to better dispersibility, but slower disintegration than Kollidon 12. It is
found  that  ionic  surfactant  resulted  in  better  dispersibility  than  a  neutral
surfactant,  probably  due  to  charge  dispersion.  Kollidon  30  gives  better  drug
dispersion  than  hydroxypropylmethyl  cellulose  and  hydroxypropyl  cellulose.
Dense  granules  were  formed  when  the  disintegrant,  Polyplasdone,  was  added
intra-granularly.  As the extra-granular portion of the disintegrant increases,  the
dispersibility of the drug increases as well. A 3-factor face-centered experimental
design was conducted to optimize the levels of surfactant (SLS), binder (Kollidon
30) and disintegrant (Polyplasdone). The level of Polyplasdone has no significant
impact  on  the  dispersibility  of  micronized  drug;  however,  higher  levels  of
Polyplasdone lead to significantly harder tablets. (45)
23. G.  Abdelbary,  C.  Eouani,  P.  Prinderre,  J.  Joachim,  Jp.  Reynier,  Ph.
Piccerelle determined the in vitro disintegration profile of rapidly disintegrating
tablets and found out correlation with oral disintegration.  Results obtained when
artificial saliva at 37  ◦C was employed as disintegration medium were used to
correlate the in vitro (t2) and oral disintegration times. Excellent correlation was
found and  in  addition,  we  were  able  to  achieve  a  qualitative  measure  of  the
mouthfeel by comparing the thickness of the tablets and the penetration distance
obtained  from  the  disintegration  profile.  This  method  also  permitted  the
discrimination  between  different  RDT,  where  differences  in  the  disintegration
mechanism were reflected on the disintegration profile achieved for each tablet.(46)
24. Jinichi Fukami , Etsuo Yonemochi , Yasuo Yoshihashi , Katsuhide Terada
prepared a rapidly disintegration tablet using a glycine as a disintegrant. Wetting
time prepared from carboxymethylcellulose (NS-300) having the hardness of 4 kg
was  3 s.  Tablet  containing NS-300 showed fastest  disintegration  compared  to
other  formulations.  These  results  suggested  that  NS-300  possessed  excellent
wetting nature and resulted in the rapid disintegration of tablet. Ethenzamide and
ascorbic  acid  were  added to the formulation,  and their  disintegration behavior
were evaluated. Ethenzamide did not affect the disintegration property, however,
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ascorbic  acid  prolonged  disintegration  time.  It  was  suggested  that  the  tablet
formulation  containing  NS-300  and  glycine  was  highly  applicable  to  water-
insoluble drug, such as ethenzamide.(47)
25. Yoshio  Kuno  ,  Masazumi  Kojima  ,  Hiroaki  Nakagami  ,  Etsuo  Yonemochi  ,
Katsuhide Terada evaluated the effect of lubricants on the characteristics of orally
disintegrating  (OD)  tablets  manufactured  using  the  phase  transition  of  sugar
alcohol. OD tablets were produced by directly compressing a mixture containing
lactose–xylitol  granules,  disintegrant,  glidant  and  lubricant,  and  subsequent
heating.  The  effect  of  the  type  of  lubricant  on  the  tablet  characteristics  was
evaluated using magnesium stearate (Mg-St), sodium stearyl fumarate (SSF), and
talc as lubricants.  The hardness of the tablets increased to 6 kp as a  result  of
heating, regardless of the kind of lubricant. The oral disintegration time of the
tablets containing Mg-St or SSF increased with an increase in the hardness. In
contrast, the oral disintegration time of the tablets containing talc was not changed
despite  of  an  increase  in  hardness.  The  water  absorption  rate  of  the  tablets
containing  talc  was  much  faster  than  that  of  the  tablets  containing  other
lubricants.  Talc  was  demonstrated  to  be  the  most  desirable  lubricant  for  the
preparation of OD tablets based on the principle of the phase transition of sugar
alcohol. (48)
26. Sameer G. Late, Yi-Ying Yu, Ajay K. Banga I Sameer G. Late, Yi-Ying Yu, Ajay
K.  Banga  investigated  the  effects  of  calcium silicate  (disintegration-promoting
agent)  and  various  lubricants  on  an  optimized  cyclodextrin-based  fast-
disintegrating  tablet  formulation.  Effects  of  moisture  treatment  were  also
evaluated at 75, 85 and 95% relative humidities. A two factor, three levels full
factorial  design  was  used  to  optimize  concentrations  of  calcium  silicate  and
lubricant.  Magnesium  stearate,  being  commonly  used  lubricant,  was  used  to
optimize  lubricant  concentration  in  optimization  study  and  revealed  that
concentration  of  calcium  silicate  had  no  effect;  however  concentration  of
lubricant was found to be important  for  tablet  disintegration and hardness.  An
optimized value of 1.5% of magnesium stearate gave disintegration time of 23.4 s
and hardness of 1.42 kg. (49)
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27. Yoshio Kuno, Masazumi Kojima, Shuichi Ando, Hiroaki Nakagami evaluated
the properties of rapidly disintegrating (RD) tablets manufactured by the phase
transition  method.The  results  suggested  that  the  heating  process  and  xylitol
content  might  influence  the properties  of  RD tablets.  They also evaluated  the
physicochemical  properties  of  the RD tablets,  including the median pore  size,
crystallinity,  hardness,  and  oral  disintegration  time  of  tablets  made  with  and
without heating. After heating, the median pore size of the tablets was increased
and  tablet  hardness  was  also  increased.  The  increase  of  tablet  hardness  with
heating and storage did not depend on the crystal state of the lower melting point
sugar alcohol. It is concluded that a combination of low and high melting point
sugar  alcohols,  as well  as a phase transition in the manufacturing process,  are
important for making RD tablets without any special apparatus. (50)
28. Masaaki  Sugimoto,  Toru  Maejima,  Shinji  Narisawa,  Koji
Matsubara,Hiroyuki  Yoshino et  al investigated  the  factors  affecting  the
characteristics  of  rapidly  disintegrating  tablets  containing an  amorphous
ingredient prepared by crystalline transition method (CTM) under various storage
conditions.  Effect  of  storage  conditions  and  formulating  ratio  of  amorphous
sucrose on the characteristic changes (tensile strength, porosity, and disintegration
time) of the rapidly disintegrating tablets was studied. The storage conditions of
different temperature and humidity affected the rate of crystalline transition and
the  increase  in  the  tablet  tensile  strength.  The  higher  formulating  ratio  of
amorphous sucrose provided the longer disintegration time in the mouth. They
concluded that the formulating ratio of 10–20% of the amorphous sucrose in the
tablet is suitable for the rapidly disintegrating tablet in the mouth when prepared
by CTM. (50)
29. Simone  Schiermeier,  Peter  Christian  Schmidt  formulated  water  dispersible
tablet  and  orodispersible  tablet  of  coated  Ibuprofen  by  direct  compression
method. The properties of the water dispersible tablet, such as porosity, hardness,
disintegration time and increase in viscosity after dispersion, were investigated.
The  selected  tablet  formulation,  containing  26%  galactomannan  and  5%
crospovidone,  disintegrates  before  the  galactomannan  starts  to  swell.  These
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tablets disperse in water within 40 s and show a crushing strength of 95 N. An
optimum Orodispersable tablet formulation, containing 34% mannitol and 13%
crospovidone,  provides  a  short  wetting time of  17 s and a sufficient  crushing
strength of 40 N. (51)
30. Takao  Mizumotoa,  Yoshinori  Masudaa,  Takeshi  Yamamotob,  Estuo
Yonemochi,  Katsuhide  Terada investigated  a  novel  fast-disintegrating  tablet
through improvement of compressibility of low compressibility saccharides,  by
coating and granulating the same with a high one to enable the production of a
fast-disintegrating  tablet.  Another  discovery  was  that  the  high-compressibility
saccharide used as a binder solution was present in an amorphous state after the
granulation  process.  The  crystal  change  from  amorphous  to  crystal  state
intentionally  by  a  conditioning  process  after  compression  enabled  to  increase
tablet  hardness  by strengthening  adhesion  between  particles.  The  conditioning
process made it possible to achieve sufficient hardness while maintaining the fast
disintegration  time.  As  a  result,  this  fast-disintegrating  tablet  that  can  be
manufactured by commonly used equipment, can be used for the dosing of a wide
range drugs. (52)
31. Iman Saad Ahmed, Mona Hassan Aboul-Einien developed a fast-disintegrating
lyophilized dry emulsion (LDE) tablet to enhance the in vitro dissolution and in
vivo absorption of Griseofulvin. In this study, the rate of absorption of GF from
LDE tablet was faster than that from the reference tablet and had significantly
higher  (p  = 0.02) peak plasma concentration and shorter time to  C  max  by 4 h.
Stability results, after 6 months storage of LDE tablets at 25 ◦C and 60% relative
humidity,  showed a slight increase in disintegration time and residual moisture
content, while results from dissolution studies showed slightly slower initial drug
release.(53)
32. Hisakadzu Sunada and Yunxia Bi developed rapidly disintegrating tablets using
both direct compression and wet compression methods. Tablet properties, such as
porosity,  tensile strength,  wetting time and disintegration time were evaluated,
and the formation and disintegration mechanisms of the tablets were elucidated.
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Formulation  and  preparation  conditions  were  optimized  using  polynomial
regression or artificial neural network  ANN.(54)
33. Rahul Chandrasekhar,  Zahra Hassan,  Farhan AlHusban,  Alan M. Smith,
Afzal R. Mohammed developed and optimized FDTs using gelatin and BSG in
single and combination at 1st stage. A combination (5% gelatin) FDT comprising
a 50:50 ratio of 75:225 BSGs (hardness: 13.7 ± 0.9 N and disintegration time:
24.1 ± 0.6 s) was judged the most ideal, and was carried forward to Stage II: the
addition  of  the  saccharides  sorbitol,  mannitol  and  sucrose  in  concentrations
between  10% and 80% w/w. The best  properties  were  exhibited by mannitol-
containing formulations  (50%-hardness:  30.9 ± 2.8  N and disintegration  time:
13.3  ±  2.1  s),  which  were  carried  forward  to  the  next  stage:  the  addition  of
viscosity-modifying  polymers  to  improve  mouth-feel  and  aid  pre-gastric
retention. Addition of carbopol 974P-NF resulted in the enhancement of viscosity
with a compromise of the hardness of the tablet,  whereas Pluronic F127 (6%)
showed  an  increase  in  disintegration  time  and  viscosity  with  retention  of
mechanical properties. (55)
34. Vijay Sharma, Anil K. Philip and Kamla Pathak developed a orodispersible
tablet of roxithromycin, using modified polysaccharides as rapidly disintegrating
excipients.  Modified polysaccharides  co grinded treated  agar  (C-TAG) and  co
grinded  treated  guar  gum  (C-TGG)  were  prepared  by  subjecting  pure
polysaccharides namely agar and guar gum respectively to sequential processes of
wetting, drying and co grinding with mannitol (1:1). Results indicated that lower
levels of modified polysaccharides namely C-TAG in F3 and C-TGG in F7 and
higher  levels  of  microcrystalline  cellulose,  exhibited  least  disintegration  times
without friability concerns. In vitro release of optimized formulations F3 and F7,
both at salivary pH and physiological pH was found to be more than 90% within
30  min  as  compared  to  27.82%  at  the  same  time  point  of  conventional
formulation. (56)
35. Honey  Goel,  Nishant  Vora,  and  Vikas  Rana developed  and  optimized  fast
disintegrating tablets of Ondansetron HCl (water soluble) or domperidone (water
insoluble) using aminoacetic acid, carmellose and sodium alginate with enough
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mechanical  strength  and their  disintegration  behaviour  was  evaluated.  Plackett
Burman  Screening  Design  was  used  to  screen  the  independent  active  process
which  were  found  to  actively  influence  the  dependent  variables.  Also,  the
coefficients of active variables of FDTs containing domperidone was found to be
significantly  different  from  the  coefficients  of  active  factors  containing
ondansetron  HCl  FDTs.  Further,  FDTs  containing  domperidone  was  prepared
according to central composite design for estimating the effect of active factors in
extended spherical domain. The regression analysis of quadratic fit revealed that
DT,  WT  and  WAR  were  98%  correlated  with  active  factors.The  optimized
domperidone  FDTs  were  further  compared  with  superdisintegrants.  The  data
revealed that optimized domperidone FDTs were better than domperidone FDTs
containing  croscarmellose  or  crospovidone.  Hence,  this  novel  excipients
combination  can  be  used  for  delivery  of  water  insoluble  drugs  in  place  of
superdisintegrants.(57)
36. Omaima  A.  Sammour,  Mohammed  A.  Hammad,  Nagia  A.  Megrab,  and
Ahmed S. Zidan prepared the MDT of rofecoxib using of its solid dispersion
with polyvinyl pyrrolidone K30 (PVP K30) using solvent evaporation method. In
an attempt to construct a statistical model for the prediction of disintegration time
and percentage friability, a 32 randomized full and reduced factorial design was
used to optimize the influence of the amounts of superdisintegrant and subliming
agent..  Concerning  the  optimization  study,  the  multiple  regression  analysis
revealed that an optimum concentration of camphor and a higher percentage of
crospovidone  are  required  for  obtaining  rapidly  disintegrating  tablets.  In
conclusion, this investigation demonstrated the potential of experimental design in
understanding  the  effect  of  the  formulation variables  on  the  quality  of  mouth
dissolve tablets containing solid dispersion of a hydrophobic drug. (58)
37. G. Abdelbary, P. Prinderre,  C. Eouani, J. Joachim, J. P.  Reynier and Ph.
Piccerelle described a new approach to prepare RDT with sufficient mechanical
integrity, involving the use of a hydrophilic waxy binder (Superpolystate©, PEG-
6-stearate). The incorporation of Superpolystate® in the formulation of RDT was
realised by means of two different granulation methods: wet granulation by using
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an emulsion of this waxy binder as granulating liquid and melt granulation where
the molten form of the binder was used. The potential of the intragranular addition
of  croscarmellose  sodium  as  a  disintegrating  agent  was  also  evaluated.  The
subsequent step encompassed the preparation and the evaluation of the tablets,
including the effect of the extragranular introduction of croscarmellose sodium.
An  improvement  in  tablet  hardness  and  friability  was  observed  with  both
granulation methods where they were able to obtain RDT with a disintegration
time of 40±2 s and a hardness of 47.9±2.5N. (59)
38. Mutasem  M.  Rawas-Qalaji,  F.  Estelle  R.  Simons,  and  Keith  J.  Simons
evaluated the effect of increasing epinephrine load on the characteristics of fast-
isintegrating  sublingual  tablets.  Four  tablet  formulations,  A,  B,  C,  and  D,
containing 0%, 6%, 12%, and 24% of epinephrine bitartrate,  respectively,  and
microcrystalline  cellulose,  low-substituted  hydroxypropyl  cellulose  (9:1),  were
prepared  by  direct  compression,  at  a  range  of  compression  forces.  A  linear
increase in compression force resulted in an exponential increase in hardness for
all formulations, a linear increase in disintegration and wetting times of A, and an
exponential increase in disintegration and wetting times of B, C, and D. Tablets
with drug loads from 0% to 24% epinephrine can be formulated with hardness,
disintegration times, and wetting times suitable for sublingual administration. (60)
39. Ashok  R.  Patel  and  Pradeep  R.  Vavia  evaluated  the  potential  of  ternary
complexation as an approach for taste masking. For this purpose famotidine with
property  of  bitter  taste  was  selected  as  a  model  drug.  Improvement  in  taste
masking  capability  of  cyclodextrin  towards  famotidine  was  evaluated  by
formulating a ternary complex  including hydrophilic  polymer  hydroxyl  propyl
methyl cellulose (HPMC 5 cps) as the third component. Taste perception study
was  carried  out  on  human volunteers  to  evaluate  the  taste  masking ability  of
ternary  complexation.  Ternary  system  showed  effective  taste  masking  as
compared to binary complex and at the same time showed no limiting effect on
the drug release (D.E15min=90%). The effective taste masking was attributed to
the enhanced complexation of famotidine in ternary system compared to binary
system  and  the  same  was  confirmed  from  the  characterization  studies.  In
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conclusion, the study confirmed that ternary complexation can be utilized as an
alternative approach for effective taste masking. (61)
40. U.S.  Patent  No.  4,910,023  to  Botzolakis  et.  al. discloses  a  pharmaceutical
preparation comprising a poor tasting hygroscopic drug that is taste masked using
from about 3% to about 30% by weight of silicon dioxide adsorbed onto the drug
particle. The pharmaceutical composition is administered as swallowable capsule
or tablet wherein the drug is present in amounts of from 30 to 70% of the total
composition. (62)
41. U.S. Patent No. 4,786,508 to Ghebre-Sellassie et. al. discloses taste masking of
bitter tasting drugs in oral dosage forms using a polymeric coating component that
contains a cationic copolymer with residues of (meth)acrylic ester and dimethyl
aminoethyl(meth)  acrylate.  The polymeric coating is  saliva resistant  yet  a acid
soluble for protection in the mouth and buccal area but ingestible once swallowed.
(63)  
42. U.S patent No. 5,681,577 to Lech Stanley et. al discloses an improved chewable
cold  /sinus  medication  comprising  a  decongestant  pseudoephedrine  ,  and  an
antihistamine,  such  as  chlorpheniramine  maleate  or  diphenhydramine
hydrochloride. The drugs are  incorporated onto an adsorbant material comprising
silicon dioxide which surprisingly masks their bitter metallic taste and numbing
mouth feel that would otherwise prohibit their use in a chewable tablet dosage
form. (64) 
43. U.S Paten No. 6,001,392 to Wen et. al. proposes a mixture of coated and non
coated  sulphonic acid cation exchange resins cross- linked with divinyl benzene
on to which dextromethorphan has been loaded. (65) 
44. U.S  patent  no.  651,4492  to  Gao  et.  al.  discloses  formulation  of  oral  liquid
product using ion exchange resins as carriers for eliminating the bitter taste of
quinolone. (66)
45. U.S Patent No. 5,529,783 to Burke et. al. discloses chewable tablet formulations
comprising  individual  taste  masked  coated  granules  of  acetaminophen,
chlorpheniramine, pseudoephedrine and dextromethorphan. (67)
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46. U.S Patent No. 5466464 to Masaki et. al. discloses a solid preparation soluble in
buccal cavity, which ic composed of a sugar comprising lactose and or moannitol
and 0.1-1.2% of agar and active ingredient and has a density of 400-1000 mg/ml
and such a strength to withstand handling in the manufacture thereof.(68) 
47. A. Abdelbary, A.H. Elshafeey , G. Zidan studied the Comparative effects of
different  cellulosic-based  directly  compressed  orodispersable  tablets  on  oral
bioavailability of famotidine. A 32 full factorial design was used to evaluate the
influence  of  different  excipients  on  the  properties  and  in  vitro  dissolution  of
famotidine ODT. Two factors were studied for their qualitative effects, namely,
disintegrants and diluents. Disintegrants were studied in three levels viz. Ac-Di-
Sol,  sodium  starch  glycolate  (Primojel)  and  low-substituted  hydroxypropyl
cellulose (L-HPC). Fillers were studied in three levels viz. mannitol, spray dried
lactose and Avicel PH 101. The ODTs were prepared by direct compression and
were  evaluated  for  hardness,  drug  content,  uniformity  of  weight,  in  vitro
disintegration time, oral disintegration time, wetting time and in vitro dissolution.
Maximum  dissolution  and  minimum  oral  disintegration  time  (11.4  s)  were
observed in F7 prepared using L-HPC and mannitol. (69) 
48. Sishu  et.  al. prepared  fast  disintegrating  tablets  of  Diazepam  using  MCC as
directly  compressible  filler  and SSG as  super  disintegrants.  The  tatse  masked
microspheres  were  prepared  using  Eudragit  E-100  by  solvent  evaporation
technique. Successful  FTD shows good taste and invivo disintegrating time 30
seconds. (70) 
AIM & OBJECTIVE
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 Formulation  development  and  evaluation  of  orally
disintegrating tablets of Dextromethorphan HBr.
 Since the taste of the drug is very bitter, suitable method for
taste  masking  is  to  be  developed  prior  to  formulation
development.
 The in vitro disintegration time is to be maintained within 30
seconds.
 Smooth  mouth  feel  is  to  be  obtained  during  in  vivo
disintegration.
 Optimization of sweeteners and flavors to obtain a palatable
formulation.
PLAN OF WORK
The scheme of proposed work is as fallows:
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 API Characterization
• Organoleptic Properties
 Taste-masking of API
• By using Ion-exchange Resins
• By using β-cyclodextrin
• By using magnesium trisilicate.
 Characterization of   API and taste masked API and pre-formulation studies
• Physico mechanical characterization
• Particle size distribution
• Drug excipient compatible study
• Moisture content 
 Formulation of ODT
 Evaluation of ODT
• Weight variation.
• Thickness
• Hardness
• Friability
• Disintegration time (DT)
• Taste of ODT
• Assay
• In vitro drug release.   
 Stability study
DRUG PPOFILE (72-83)
Dextromethorphan Hydrobromide
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Structure:
Chemical Name: 3-methoxy-17-methyl-9,13,  14  morphinian  hydrobromide
monohydrate   
Molecular Formula: C18H25NO ·HBr· H2O 
Molecular Weight: 370.32
Physical Appearance: A practically white to slightly yellow, odorless, crystalline
 powder
Solubility: 1 in 65 of water; freely soluble in   alcohol and in 
chloroform; insoluble in ether
λmax :  278nm
pH: 1% solution in water is between 5.2 and 6.5
Dose: 10 to 20 mg every 4 hours, or 30 mg every 6 to 8 hours, to 
a usual   maximum of 120 mg in 24hours.
Bioavailability: 11%
Half life: 1.4- 3.9 hours 
Taste: Bitter
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Action & Use: The primary use of Dextromethorphan is as a cough suppressant, for the
temporary relief of cough caused by minor throat and bronchial irritation (as commonly
accompanies the common cold), as well as other causes such as inhaled irritants.
Pharmacology:  Dextromethorphan is the dextrorotary-enantiomer of the opioid-receptor
agonist levomethorphan  .  Unlike  most  opioids,  it  has  not  been  reported  to  possess
significant  analgesic properties  or  dependence-liability.  It  is,  however,  a  potent
antitussive and has largely replaced  codeine in  this indication.  It  is  perhaps the most
widely available and used antitussive currently marketed.
An  active  metabolite of  Dextromethorphan  is  Dextrorphan,  the  3-hydroxy
derivative of  Dextromethorphan.  The  effects  of  Dextromethorphan are  believed to be
caused by both Dextromethorphan and Dextrorphan. Dextromethorphan is predominantly
metabolized by the  liver, by the hepatic  cytochrome P450 enzyme known as  CYP2D6.
There is a significant proportion of the population who has a functional deficiency in this
enzyme (CYP2D6 poor metabolizers). As CYP2D6 is the primary metabolic pathway in
the  inactivation  of  Dextromethorphan,  the  duration  of  action  and  effects  of
Dextromethorphan  are  significantly  increased  in  such  poor  metabolizers.  Deaths  and
hospitalizations have been reported in poor metabolizer recreational users. 
A large number of medications (including antidepressants) are potent inhibitors of
CYP2D6.  There  exists,  therefore,  the  potential  of  drug-drug  interactions  between
dextromethorphan  and  concomitant  medications.  There  have  been  reports  of  fatal
consequences arising from such interactions. 
Dextromethorphan  crosses  the  blood-brain  barrier,  and the following pharmacological
actions have been reported: 
• NMDA glutamatergic receptor antagonist 
• dopamine reuptake inhibitor 
• σ1 and σ2 receptor agonist 
• α3β4 nicotinic receptor antagonist 
• serotonin reuptake inhibitor 
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Drug Interaction: Dextromethorphan  should  not  be  used  (either  recreationally  or  at
normal  dosage  levels)  by  people  who  are  taking  a  monoamine  oxidase  inhibitor.
Combining DXM and a MAOI has been fatal.  Fluoxetine (Prozac™) is a cytochrome
P450-2D6  inhibitor,  and  will  change  the  characteristics  of  a  Dextromethorphan  trip
somewhat.  The duration of the trip may be greatly extended by P450-2D6 inhibitors;
some  users  have  reported  effects  lasting  12  to  24  hours  past  the  normal  duration.
Dextromethorphan should not be taken (recreationally or at normal dosage levels) with
the prescription antihistamine Terfenadine (Seldane™). The reason for this interaction
seems to be that terfenadine, which is normally metabolized by a P450 enzyme, induces
heart irregularities when it builds up. Dextromethorphan may saturate the P450 enzymes
that normally metabolize terfenadine. 
ADR: High doses of ths drug can cause ataxia, respiratory depression and convulsions in
children,  while  in  adults  high  doses  can  alter  sensory  perceptions  and  cause  ataxia,
slurred speech and dysphoria. The side effects include slight drowsiness and G.I upset. 
Use  in  Different  Pathological  Conditions: Dextromethorphan  is  commonly  used  to
determine  cytochrome  P450-2D6 activity.  Cytochrome  P450-2D6,  or  debrisoquine  4-
hydroxylase, is a liver enzyme which converts DXM into dextrorphan, and is extensively
involved  in  the  metabolism  of  other  drugs.  By  looking  at  the  metabolites  of
Dextromethorphan,  a  physician  can  determine  P450-2D6  efficiency,  and  adjust  drug
dosage to match. 
One area in which Dextromethorphan shows great promise is in the prevention of brain
damage resulting from excitotoxicity (over-stimulation of nerve cells to the point of cell
death) and other types of nerve cell damage. Dextromethorphan may reduce or eliminate
the brain  damage resulting from conditions such as  fever,  hypoxia (lack  of  oxygen),
ischemia (cutoff of blood to brain cells), physical injury, infection (such as poliomyelitis,
encephalitis, and mceningitis), stroke, seizure, drug toxicity, and withdrawal from long-
term dependence upon certain drugs (notably alcohol, barbiturates, and benzodiazepines
such as Valium™). 
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In the case of infection (and in particular poliomyelitis), it has been demonstrated that the
damage  to  the  CNS  often  occurs  not  from  the  infection,  but  from  the  body's  own
defenses, and notably from a chemical called quinolinic acid (a metabolite of tryptophan).
Quinolinic acid is a very potent agonist (activator) at excitatory amino acid receptors, of
which NMDA is one type; Dextromethorphan prevents quinolinic acid from activating
NMDA receptors. 
Dextromethorphan is currently being evaluated as an anticonvulsant. Preliminary studies
in humans indicate that  even very low levels of Dextromethorphan may help prevent
seizures. This effect is not due to NMDA receptors; instead, it is probably due to sigma
receptors or voltage-gated ion channels. 
Another new area where Dextromethorphan has potential is in combating the withdrawal
symptoms of opiate addiction. Dextromethorphan plus diazepam (Valium™) was more
effective  at  combating  the  symptoms  of  heroin  withdrawal  than  chlorpromazine
(Thorazine™) plus diazepam. This is most likely due to Dextromethorphan's ability to
block NMDA receptors. Dextromethorphan has shown some potential for treating some
of the problems associated with mental  retardation.  It  may also be of use in treating
Parkinson's disease and ALS (Lou Gehrig's Disease). DXM may be useful in conjunction
with opiates for alleviation of both acute and chronic pain.  It  may even be useful  in
fighting lung cancer. 
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EXCIPIENT PROFILE
MANNITOL (84)
1. Nonproprietary Names:
BP JP PhEur USP
Mannitol D-Mannite: Mannitolum: Mannitol
2. Synonyms: Cordycepic acid;  E421; D-mannitol; manna sugar; mannite; Pearlitol.
3. Chemical Name and CAS Registry Number: D-Mannitol [69-65-8]
4. Empirical Formula: C6H14O6       
5. Molecular Weight: 182.17
6. Structural Formula:
7. Functional Category:  Sweetening agent; tablet and capsule diluent; tonicity agent;
vehicle (bulking agent) for lyophilized preparations.
8. Applications in Pharmaceutical  Formulation or Technology: Mannitol is widely
used in pharmaceutical formulations and food products. In pharmaceutical preparations it
is  primarily  used  as  a  diluent  (10-90%  w/w)  in  tablet  formulations,  where  it  is  of
particular value since it is not hygroscopic and may thus be used with moisture-sensitive
active ingredients.
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Mannitol  may be used in direct-compression tablet  applications,  for which the
granular  and  spray-dried  forms  are  available,  or  in  wet  granulations.  Granulations
containing mannitol have the advantage of being dried easily. Specific tablet applications
include  antacid  preparations,  glyceryl  trinitrate  tablets,  and  vitamin  preparations.
Mannitol  is  commonly  used  as  an  excipient  in  the  manufacture  of  chewable  tablet
formulations because of its negative heat of solution, sweetness, and ‘mouth feel’.
In lyophilized preparations, mannitol (20-90% w/w) has been included as a carrier
to produce a stiff,  homogeneous cake that improves the appearance of the lyophilized
plug in a vial. A pyrogen-free form is available specifically for this use.
9. Description: Mannitol occurs as a white, odorless, crystalline powder, or free-flowing
granules. It  has a sweet taste, approximately as sweet as glucose and half as sweet as
sucrose,  and imparts a cooling sensation in the mouth.  Microscopically,  it  appears  as
orthorhombic needles when crystallized from alcohol.
10. Typical Properties:
      Density (bulk): 0.430 g/cm3 for powder; 0.7 g/cm3 for granules.
      Density (tapped): 0.734 g/cm3 for powder; 0.8 g/cm3for granules
      Density (true): 1.514 g/cm3
      Dissociation constant: pKa = 13.5 at 18°C
      Flowability: Powder is cohesive, granules are free flowing.
      Melting point: 166-168°C
       Solubility: Table-2: Solubility of Mannitol
Solvent Solubility at 20°C
Alkalis Soluble
Ethanol (95%) 1 in 83
Ether Practically insoluble
Glycerin 1 in 18
Water 1 in 5.5
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     Specific surface area: 0.37-0.39 m2/g
Fig-5: SEM images of mannitol (Powder and granular).
SEM-Mannitol powder SEM-Mannitol granular
Manufacturer: SPI Pharma Manufacturer: SPI Pharma
11. Stability and Storage Conditions: Mannitol is stable in the dry state and in aqueous
solutions. Mannitol  does not undergo Maillard reactions.  The bulk material should be
stored in a well-closed container in a cool, dry, place.
12.  Incompatibilities: None  reported  in  the  dry  state.  Reducing  sugar  impurities  in
mannitol have been implicated in the oxidative degradation of a peptide in a lyophilized
formation.
13.  Handling  Precautions: Mannitol  may  be  irritant  to  the  eyes;  eye  protection  is
recommended.
14. Regulatory Status: GRAS listed. Accepted for use as a food additive in Europe.
Included in the FDA Inactive Ingredients Guide (IP, IM, IV, and SC injections, infusions,
buccal,  oral  and  sublingual  tablets  and  capsules).  Included  in  nonparenteral  and
parenteral medicines licensed in the UK.
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CROSSPOVIDONE(85)
Nonproprietary Names:
BP      PhEur USP
Crospovidone       Crospovidone                     Crospovidone
2. Synonyms:
Cross-linked  povidone;  Kollidon CL;  Polyplasdone  XL;  Polyplasdone  XL-10;
polyvinylpolypyrrolidone; PVPP; 1-vinyl- 2-pyrrolidinone homopolymer.
3.  Chemical  Name  and  CAS  Registry  Number:  1-Ethenyl-2-pyrrolidinone
homopolymer [9003-39-8]
4. Empirical Formula: (C6H9NO)n     
    Molecular Weight: > 1 000  
Crospovidone  is  a  water-insoluble  synthetic  crosslinked  homopolymer  of  N-vinyl-2-
pyrrolidinone. An exact determination of the molecular weight has not been established
because of the insolubility of the material.
5. Structural Formula:
:  
6. Functional Category: Tablet disintegrant.
7. Applications in Pharmaceutical  Formulation or Technology: Crospovidone is  a
water-insoluble  tablet  disintegrant  used  at  2-5% concentration  in  tablets  prepared  by
direct  compression  or  wet  and  dry  granulation  methods.(1-4) It  rapidly  exhibits  high
capillary activity and pronounced hydration capacity with little tendency to form gels.
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8. Description: Crospovidone is a white to creamy-white, finely divided, free- flowing,
practically tasteless, odorless or nearly odorless, hygroscopic powder.
10. Typical Properties
       Acidity/alkalinity: pH = 5.0-8.0 (1% w/v aqueous slurry)
      Compression pressure: 20.39 kN/cm2
      Tensile strength: 0.7471 kN/cm2
      Permanent deformation pressure: 140.4 kN/cm2
      Brittle fracture index: 0.2371
      Bonding index: 0.0053
      Reduced modulus of elasticity: 10621
      Density: 1.22 g/cm3
      Density (bulk): 0.213 g/cm3 for Polyplasdone XL; 
0.323 g/cm3 for Polyplasdone XL-10.
      Density (tapped): 0.273 g/cm3 for Polyplasdone XL; 
0.461 g/cm3 for Polyplasdone XL-10.
      Moisture content: Approximately 60%.
      Particle size distribution: Less than 400 µm for Polyplasdone XL; less than 74 µm
for Polyplasdone XL-10. Approximately 50% greater than 50 µm and maximum of 1%
greater than 250 µm in size for Kollidon CL.
      Solubility: practically insoluble in water and most common organic solvents.
      Specific surface area: 0.77-0.82 m2/g 
11.  Stability  and Storage  Conditions: Crospovidone is  stable.  However,  since  it  is
hygroscopic it should be stored in an airtight container in a cool, dry, place.
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12.  Incompatibilities: Crospovidone  is  compatible  with  most  organic  and  inorganic
pharmaceutical ingredients. When exposed to a high water level crospovidone may form
molecular adducts with some materials.
13. Handling Precautions: Observe normal precautions appropriate to the circumstances
and  quantity  of  material  handled.  Eye  protection,  gloves,  and  a  dust  mask  are
recommended.
14. Regulatory Status: Included in the FDA Inactive Ingredients Guide (oral capsules
and tablets, topical, transdermal, and vaginal preparations).
15. Pharmacopeias: Eur and US.
CROSCARMELLOSE SODIUM(86)
1. Nonproprietary Names:
BP JPE USP
Croscarmellose sodium Croscarmellose sodium Croscarmellose sodium
2. Synonyms: Ac-Di-Sol; crosslinked carboxymethylcellulose sodium; modified 
cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab.
3.  Chemical  Name  and  CAS  Registry  Number: Cellulose,  carboxymethyl  ether,
sodium salt, crosslinked [74811-65-7]
4. Empirical Formula:The USP describes carboxymethylcellulose sodium as the sodium
salt of polycarboxymethyl ether of cellulose.
      Molecular Weight: 90 000-700 000.
5. Structural Formula:
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6. Functional Category: Tablet and capsule disintegrant.
7. Applications in Pharmaceutical Formulation or Technology:
Croscarmellose sodium is used in oral pharmaceutical formulations as a disintegrant for
capsules  (10-12%w/w),  tablets  (0.5-5%w/w),  and  granules.  In  tablet  formulations,
croscarmellose  sodium  may  be  used  in  both  direct-compression(2%)  and  wet-
granulation(3%) processes. When used in wet granulations the croscarmellose sodium is
best added in both the wet and dry stages of the process (intra- and extragranularly) so
that the wicking and swelling ability of the disintegrant is best utilized. 
8.   Description: Croscarmellose sodium occurs as an odorless, white-colored powder.
10. Typical Properties:
      Bonding index: 0.0456
      Brittle fracture index: 0.1000
      Compression pressure: 20 kN/cm2
      Permanent deformation pressure: 29.9 kN/cm2
      Reduced modulus of elasticity: 960
      Tensile strength: 1.3605 kN/cm2
      Density (bulk): 0.529 g/cm3 for Ac-Di-Sol
      Density (tapped): 0.819 g/cm3 for Ac-Di-Sol
      Density (true): 1.543 g/cm3 for Ac-Di-Sol
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      Particle size distribution: Not more than 2% retained on a #200 (73.7 µm) mesh and
not more than 10% retained on a #325 (44.5 µm) mesh, for Ac-Di-Sol. More than 90%
less than 45 µm, and more than 98% less than 100 µm in size, for Pharmacel XL.
      Solubility: Insoluble in water, although croscarmellose sodium rapidly swells to 4-8
times its original volume on contact with water.
      Specific surface area: 0.81-0.83m2/g
11.  Stability  and  Storage  Conditions: Croscarmellose  sodium  is  a  stable  though
hygroscopic material. Croscarmellose sodium should be stored in a well-closed container
in a cool, dry, place.
12. Incompatibilities: The efficacy of disintegrants, such as croscarmellose sodium, may
be slightly reduced in tablet formulations prepared by either wet-granulation or direct-
compression  process  which  contains  hygroscopic  excipients  such  as  sorbitol.
Croscarmellose sodium is not compatible with strong acids or with soluble salts of iron
and some other metals such as aluminum, mercury, and zinc.
13. Handling Precautions: Observe normal precautions appropriate to the circumstances
and quantity of material handled. Croscarmellose sodium may be irritant to the eyes; eye
protection is recommended.
14. Regulatory Status: Included in the FDA Inactive Ingredients Guide (oral capsules
and tablets). Included in nonparenteral medicines licensed in the UK.
15. Pharmacopeias: Eur and US.
48
SODIUM STARCH GLYCOLATE(87)
1. Nonproprietary Names: 
BP Ph.Eur USP
Sodium starch glycolate   Carboxymethylamylun natricum Sodium starch glycolate
2. Synonyms: Carboxymethyl starch, sodium salt; Explotab; Primojel.
3. Chemical Name and CAS Registry Number: Sodium carboxymethyl starch [9063-
38-1]
4. Empirical Formula:      
5. Molecular Weight: The USP states that sodium starch glycolate is the sodium salt of a
carboxymethyl ether of starch. The molecular weight is typically 500 000-1 000 000. 
5. Structural Formula:
 
6. Functional Category: Tablet and capsule disintegrant.
7.  Applications  in  Pharmaceutical  Formulation  or  Technology: Sodium  starch
glycolate acts as a disintegrant by rapid uptake of water followed by rapid and enormous
swelling in capsule and tablet formulations prepared by either direct-compression or wet-
granulation processes. The usual concentration employed in a formulation is between 2-
8%, with the optimum concentration about 4% although in many cases 2% is sufficient.
Although  the  effectiveness  of  many  disintegrants  is  affected  by  the  presence  of
hydrophobic excipients, such as lubricants, the disintegrant efficiency of sodium starch
glycolate is unimpaired. Increasing the tablet compression pressure also appears to have
no effect on disintegration time.
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8. Description: Sodium starch glycolate is a white to off-white, odorless, tasteless, free-
flowing powder. It  consists of oval or spherical granules, 30-100 µm in diameter with
some less-spherical granules ranging from 10-35 µm in diameter.
10. Typical Properties
Acidity/alkalinity: pH  =  3.0-5.0%  or,  pH  =  5.5-7.5%  for  a  3.3%
aqueous dispersion.
      Ash: ≤ 15%
      Density (bulk): 0.756 g/cm3(a)
      Density (tapped): 0.945 g/cm3(a)
      Density (true): 1.443 g/cm3(a)
      Melting point: Does not melt, but chars at approximately 200°C.
      Particle size distribution:  100% of particles less than 104 µm in size. Average
particle size is 42 µm for Explotab.
Solubility: Sparingly soluble in ethanol (95%); practically insoluble in water. At a
concentration of 2% w/v it disperses in cold water and settles in the form of a highly
hydrated layer.
      Specific suface area: 0.24 m2/g(a)
       Swelling capacity: In water, sodium starch glycolate swells up to 300 times its 
volume.
11. Stability and Storage Conditions: Tablets prepared with sodium starch glycolate
have good storage properties. Sodium starch glycolate is stable and should be stored in a
well-closed container to protect it from wide variations in humidity and temperature that
may cause caking. The physical properties of sodium starch glycolate remain unchanged
for up to 4 years if stored at moderate temperatures and humidity.
12. Incompatibilities: Sodium starch glycolate is incompatible with ascorbic acid.
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13.  Handling Precautions:  Sodium starch  glycolate  may be  irritant  to  the  eyes;  eye
protection and gloves are recommended. A dust mask or respirator is recommended for
processes that generate a large quantity of dust.
14. Regulatory Status: Included in the FDA Inactive Ingredients Guide (oral capsules
and tablets). Included in nonparenteral medicines licensed in the UK.
15. Pharmacopeias: China, Eur, and US.
MAGNESIUM TRISILICATE(88)
1. Nonproprietary Names:
BP          PhEur USP
Magnesium Trisilicate Magnesii trisilicas Magnesium trisilicate.
2. Synonyms: Magnesium mesotrisilicate; silicic acid, magnesium salt (1:2), hydrate.
3. Chemical Name and CAS Registry Number: Magnesium trisilicate hydrate [39365-
87-2]
4. Empirical Formula : Mg2Si3O8.xH2O, Molecular Weight: 260.86 (anhydrous)
5. Structural Formula: 2MgO.3SiO2.xH2O
6. Functional Category: Anticaking agent; glidant; therapeutic agent.
7. Applications in Pharmaceutical Formulation or Technology:
Magnesium trisilicate is used in oral pharmaceutical formulations and food products as a
glidant. It is also used therapeutically as an antacid.
8. Description:
The USP describes magnesium trisilicate as a compound of magnesium oxide and silicon
dioxide with varying proportions of water. Magnesium trisilicate occurs as an odorless
and tasteless, fine, white-colored powder which is free from grittiness.
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10. Typical Properties:
Moisture  content: Magnesium  trisilicate  is  slightly  hygroscopic.  At  relative
humidities of 15-65%, the equilibrium moisture content at 25°C is 17-23%; at relative
humidities of 75-95%, the equilibrium moisture content is 24-30%.
     Solubility: Practically insoluble in ethanol (95%) and water.
11. Stability and Storage Conditions: Stable if stored in a well-closed container in a
cool, dry, place.
12.  Incompatibilities: Magnesium trisilicate  may decrease  the  oral  bioavailability  of
drugs such as  mebeverine  hydrochloride, sucralfate,  and tetracycline,  via  chelation or
binding, when they are taken together. The dissolution rate of folic acid,  erythromycin
stearate, paracetamol, and chloroquine phosphate may be retarded by adsorption on to
magnesium  trisilicate.  Antimicrobial  preservatives,  such  as  the  parabens,  may  be
inactivated  by  the  addition  of  magnesium trisilicate.  Magnesium trisilicate  is  readily
decomposed by mineral acids.
13. Handling Precautions: Observe normal precautions appropriate to the circumstances
and quantity of material handled. Eye protection is recommended.
14. Regulatory Status: GRAS listed. Accepted for use as a food additive in the UK.
Included in the FDA Inactive Ingredients Guide (oral tablets). Included in nonparenteral
medicines licensed in the UK.
15. Pharmacopeias: China, Eur, and US.
CYCLODEXTRIN(89)
1. Nonproprietary Names:
BP PhEur USP
Beta cyclodextrin Betacyclodextrinun: Beta cyclodextrin
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2.  Synonyms: Cyclodextrin:  Cavitron;  cyclic  oligosaccharide;  cycloamylose;
cycloglucan; Encapsin; Rhodocap; Schardinger dextrin.
3. Chemical Name and CAS Registry Number:    α -Cyclodextrin: [10016-20-3]
β  - Cyclodextrin: [7585-39-9]
γ -Cyclodextrin: [17465-86-0]
4.            Empirical Formula     Molecular Weight
α-Cyclodextrin C36H60O30   972
β-Cyclodextrin: C42H70O35 1135
γ -Cyclodextrin:          C48H80O40 1297
5. Structural Formula:
R’, R’’ = -H for ‘natural’ α-, β- and γ-cyclodextrins.
R’, R” = -CH3 for methyl cyclodextrins.
R’, R” = -CHOHCH3 for hydroxyethyl cyclodextrins.
R’, R” = -CH2CHOHCH3 for 2-hydroxypropyl cyclodextrins.
6. Functional Category: Stabilizing agent; solubilizing agent, taste masking agent.
7. Applications in Pharmaceutical Formulation or Technology: Cyclodextrins may be
used to form inclusion complexes with a variety of drug molecules resulting primarily in
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improvements to dissolution and bioavailability due to enhanced solubility and improved
chemical and physical stability.Cyclodextrin inclusion complexes have also been used to
mask the unpleasant taste of active materials and to convert a liquid substance into a solid
material.However, β -cyclodextrin should not be used in parenteral formulations since it
is nephrotoxic, β -Cyclodextrin is considered to be nontoxic when administered orally
and has thus become primarily used in tablet and capsule formulations. β Cyclodextrin
derivatives tend to be nontoxic when used either orally or parenterally and the derivatives
2-hydroxypropyl- β -cyclodextrin and 3-hydroxypropyl- β -cyclodextrin are becoming of
increasing  importance  in  pharmaceutical  formulations.In  oral  tablet  formulations  β
-cyclodextrin may be used in both wet granulation and direct compression processes. β
-cyclodextrin tends to possess poor flow properties and requires a lubricant, such as 0.1%
w/w  magnesium  stearate,  when  it  is  directly  compressed.In  parenteral  formulations,
cyclodextrins have been used to produce stable and soluble preparations of drugs that
would otherwise have been formulated using a nonaqueous solvent. Cyclodextrins have
also been used in the formulation of solutions, suppositories, and cosmetics.
8.  Description: Cyclodextrins  occur  as  white,  practically  odorless,  fine  crystalline
powders,  having  a  slightly  sweet  taste.  Some  cyclodextrin  derivatives  occur  as
amorphous powders.
9. Typical properties: Table-3: Typical properties of three types of cyclodextrin
Typical Properties α cyclodextrin β cyclodextrin γ cyclodextrin
Bulk 0.526 g/cm3 0.523 g/cm3 0.568 g/cm3
Tapped 0.685 g/cm3 0.754 g/cm3 0.684 g/cm3
True 1.521 g/cm3 1.378 g/cm3 1.471 g/cm3
Melting point: 250-260°C 255-265°C 240-245°C
Moisture content:
10.2% w/w 13-15% w/w 8-18% w/w
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Specific rotation
[α]D25 +150.5° +162.0° +177.4°
Surface tension: 71 dynes/cm 71 dynes/cm 71 dynes/cm
Solubility: α-cyclodextrin: soluble 1 in 7 parts of water at 20°C, 1 in 3 at 
50°C.
 β -cyclodextrin: soluble 1 in 200 parts of propylene glycol, 1 in 50
of water at 20°C, 1 in 20 at 50°C; practically insoluble in acetone,
ethanol (95%), and methylene chloride.
γ -cyclodextrin: soluble 1 in 4.4 parts of water at 20°C, 1 in 2 at
45°C.
11.  Stability  and Storage Conditions: β  -Cyclodextrin,  and  other  cyclodextrins,  are
stable in the solid state if protected from high humidity.Cyclodextrins should be stored in
a tightly sealed container, in a cool, dry, place.
12.  Incompatibilities:  The  activity  of  some  antimicrobial  preservatives  in  aqueous
solution can be reduced in the presence of hydroxypropyl-β- cyclodextrin.
13. Handling Precautions: Observe normal precautions appropriate to the circumstances
and quantity of material handled. Cyclodextrins are fine organic powders and should be
handled in a well-ventilated environment. Efforts should be made to limit the generation
of dust which can be explosive.
14. Regulatory Status: Included in oral and rectal pharmaceutical formulations licensed
in Europe, Japan and the US.
SODIUM STEARYL FUMARATE(90)
1. Nonproprietary Names: USP: Sodium stearyl fumarate
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2.  Synonyms: Fumaric  acid,  octadecyl  ester,  sodium salt;  Pruv;  sodium monostearyl
fumarate.
3. Chemical Name and CAS Registry Number: 2-Butenedioic, monooctadecyl ester,
sodium salt [4070-80-8].
4. Empirical Formula:       Molecular Weight:
C22H39NaO4 390.5
5. Structural Formula:
6. Functional Category: Tablet and capsule lubricant.
7.  Applications  in  Pharmaceutical  Formulation  or  Technology: Sodium  stearyl
fumarate  is  used  as  a  lubricant  in  capsule  and  tablet  formulations  at  0.5-2.0%  w/w
concentration. It is also used in certain food applications.
8. Description: Sodium stearyl fumarate is a fine, white powder with agglomerates of
flat, circular-shaped particles.
10. Typical Properties:
Acidity/alkalinity: pH = 8.3 for a 5% w/v aqueous solution at 90°C.
Density: 1.107 g/cm3.
Density (bulk): 0.2-0.35 g/cm3
Density (tapped): 0.3-0.5 g/cm3
Melting point: 224-245°C (with decomposition)
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Specific surface area: 1.2-2.0 m2/g.
Solubility:                   Table-4: Solubility of SSF
Solvent Solubility at 20°C Unless
otherwise stated
Acetone Practically insoluble
Chloroform Practically insoluble
Ethanol Practically insoluble
Methanol Slightly soluble
Water 1 in 20 000 at 25°C,1 in 10 at80°C,1 in 5 at at 90°C
11. Stability and Storage Conditions: At ambient temperature, sodium stearyl fumarate
is stable for up to 3 years when stored in amber glass bottles, with polyethylene screw
caps. The bulk material should be stored in a well-closed container in a cool, dry, place.
12.  Incompatibilities: Sodium  stearyl  fumarate  is  reported  to  be  incompatible  with
chlorhexidine acetate.
13.  Handling  Precautions: Sodium  stearyl  fumarate  should  be  handled  in  a  well-
ventilated environment; eye protection is recommended.
14. Regulatory Status: GRAS listed. Permitted by the FDA for direct addition to food
for human consumption as a conditioning or stabilizing agent in various bakery products,
flour  thickened  foods,  dehydrated  potatoes,  and  processed  cereals  up to  0.2-1.0% by
weight of the food. Included in nonparenteral medicines licensed in the UK. Included in
the FDA Inactive Ingredients Guide.
15. Pharmacopeias: US
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MINT FLAVOR(91)
1. Nonproprietary Names:
BP JP PhEur USP
Racementhol dl-Menthol Mentholum racemicum Menthol
2.  Synonyms: Hexahydrothymol;  2-isopropyl-5-methylcyclohexanol;  4-isopropyl-1-
methylcyclohexan-3-ol;  3-p-menthanol;  p-menthan-  3-ol;  dl-menthol;  peppermint
camphor; racemic menthol.
3. Chemical Name and CAS Registry Number: (1RS, 2RS,5RS)- (±)-5-Methyl-2-(1-
methylethyl) cyclohexanol [15356-70-4].
4. Empirical Formula:      Molecular Weight:
C10H20O 156.27
5. Structural Formula:
6. Functional Category: Flavoring agent; therapeutic agent.
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7. Applications in Pharmaceutical  Formulation or Technology: Menthol  is  widely
used in pharmaceuticals as a flavoring agent or odor enhancer. 
Table-5: % concentration of mint flavor used in different dosage forms.
Use Concentration (%)
Inhalation 0.02-0.05
Oral suspension 0.003
Oral syrup 0.005-0.015
Tablets 0.2-0.4
Topical formulations 0.05-10.0
Toothpaste 0.4
Mouthwash 0.1-2.0
8.  Description:  It  is  a  free-flowing  or  agglomerated  crystalline  powder  or  colorless,
prismatic  or  acicular  shiny  crystals,  with  a  strong  characteristic  odor  and  taste.  The
crystalline form may change with time due to sublimation within a closed vessel.
10. Typical Properties:
      Boiling point: 212°C
      Flash point:  93°C
      Melting point: 34-36°C
      Refractive index: nD20 = 1.4615
      Solubility: Very soluble in ethanol (95%),  chloroform,  and ether;  very slightly
soluble in glycerin; practically insoluble in water.
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      Specific rotation: [α]D20: -2 to +2° (10% w/v alcoholic solution)
11.  Stability  and  Storage  Conditions: Menthol  should  be  stored  in  a  well-closed
container at a temperature not exceeding 25°C, since it sublimes readily.
12.  Incompatibilities: Incompatible  with  b-naphthol,  butylchloral  hydrate,  camphor,
chloral  hydrate,  chromium  trioxide,  phenol,  potassium  permanganate,  pyrogallol,
resorcinol, and thymol.
13.  Handling  Precautions:  May  be  harmful  by  inhalation  or  ingestion  in  large
quantities; may be irritant to the skin, eyes, and mucous membranes. Eye protection and
gloves are recommended.
14. Regulatory Status: Included  in  the FDA Inactive Ingredients  Guide.  Included  in
nonparenteral medicines licensed in the UK. Accepted for use in foods and confectionery
as a flavoring agent of natural origin.
SUCRALOSE(92)
1. Nonproprietary Names: USP NF: Sucralose
2. Synonyms: Splenda; TGS; 1’,4’, 6’- Trichloro galactosucrose; 4,1’,6’-trichloro-4,1’6’-
trideoxy- galacto-sucrose.
3.  Chemical  Name  and  CAS  Registry  Number: 1,6-  dichloro-  1,6  deoxy –β  –D-
fructofuranosyl-4-chloro-4-deoxy –α- D-galactopyraside [ 56038-13-2].
4. Empirical Formula:     Molecular Weight:
C12H19 Cl3O8 397.64
5. Structural Formula:
6. Functional Category: Sweetening agent.
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7. Applications in Pharmaceutical Formulation or Technology: Sucralose is used as a
sweetening agent in beverages, foods and pharmaceutical applications. It has sweetening
power approximately 300-1000 times that of sucrose and has no after taste. It  has no
nutritional value, is noncariogenic, and produces no glycemic response.
8. Description: It is a white to off white colored free flowing, crystalli8ne powder.
10. Typical Properties
      Melting point: 130°C for anhydrous crystalline form, 36.5°C for  
pentahydrate
      Refractive index: 1.33-1.37
      Solubility: Freely soluble in ethanol (95%), methanol, water;  
slightly soluble in ethyl acetate.
      Specific rotation: [α]20D: +84˚ to +87.5  (1%w/v aqueous solution); + 
68.2( 1.1% w/v in ethanol).
      Acidity/ Alkalinity: pH 5-6 (10%w/v aq solution at 20˚ C)
      Bulk density: 0.35gm/ cc.
      Tapped density: 0.62gm/cc
      True density: 1.63gm/cc
      Particle size distribution: 90%(<12 µ)
      Partition coefficient: log10 P: 0.51(octanol :water)
      Viscosity: 0.6-3.8 mPas.
11.  Stability  and  Storage  Conditions: Menthol  should  be  stored  in  a  well-closed
container at a temperature not exceeding 25°C, since it sublimes readily.
12. Handling Precautions: Observe normal precautions appropriate to the circumstances
and quantity of material handling.
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13. Regulatory Status: The FDA, in April 1998, approved sucralose for use as a tablet
top sweetener and as an additive in a variety of food products. In  UK, Sucralose was
authorized for use in food products on a 2 year temporary basis in march 2002. 
AMMONIUM GLYCYRRHIZINATE(93)
1.  Definition:  Mixture  of  ammonium 18a-  and  18b-glycyrrhizate  (ammonium salt  of
(20b)-3b-[[2-O-(b-D-glucopyranosyluronic  acid)-a-D-glucopyranosyluronic  acid]  oxy]-
11-oxoolean-12-en-29-oic acid), the 18b-isomer being the main component. 
2. Synonyms: Glycyrrhizic acid monoammonium salt.
3. Molecular formula: C42H65NO16  
4. Molecular weight: 840 
5. SAS Reg No: 53956-04-0   
 
6. Pharmacopoeia:         Ph Eur
7. Structure:
 8. Content:  98.0 per cent to 102.0 per cent (anhydrous substance). 
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 9.  Application: Glycyrrhizinic  acid  is  potentially  50  times  sweeter  than  sucrose.
Glycyrrhiza  is  the  active  principle  for  sweetening,  flavoring  and  pharmaceutical
applications. It is effective in treatment of peptic ulcer. It is frequently used in medicines
to mask the unpleasant flavors. 
10. Typical Properties:
  
      Appearance: White or yellowish-white, hygroscopic powder. 
  
      Solubility: Slightly soluble in water, very slightly soluble in anhydrous
ethanol,  practically  insoluble  in  acetone.  It  dissolves  in  
dilute solutions of acids and of alkali hydroxides.
 
      Melting Point: 2090 C
      Contents: 98%
      LOD: 6%
      Specific optical rotation: + 49.0 to + 54.0 (anhydrous substance).  
      Water: Maximum 6.0 per cent, determined on 0.250 g.
      Related substances: 18 α-Glycyrrhizic acid.
11. Stability: Stable in normal condition. Moisture sensitive.
12. Storage:  In an airtight container.
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EXPERIMENTAL WORK
Table-6: List of equipments & instruments used
Sl. No. Equipment Company/ /model
1 Mechanical stirrer. RZR 2041, Heidolph.
2 Vacuum pump Serve well
3 Tablet compression machine Minipress –II SF, Rimek.
4 Tablet tester Dr. Schleuniger 8m, Pharmatron.
5 Disintegration tester (USP) ED-2, Sapo, Electrolab.
6 Friabilator (USP) EF-1W, Electrolab.
7 Precision balance AB 204-S, Mettler Toledo.
8 Electromagnetic sieve shaker EM 8-8
9 Tap density tester (USP) ETD 1020, Electrolab.
10 Dissolution tester  (USP) TDT- 08l, Electrolab.
11 U. V Spectrophotometer Pharmaspec-1700, Shimadzu.
12 DSC DSC-60, Metller Toledo.
13 Laboratory centrifuge R-8C, Remi.
14 Infra red moisture analyzer MA 100, Sartorious.
15 pH meter Cyberscan 1000.
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16 Sonicator Mu 12000, markultra sonics.
17 Induction cap sealer Sigma JR, Electronic devices.
18 Microbalance MX 5, Mettler Toledo.
19 Stability chamber Thermolab.
Table-7: List of materials used and their suppliers.
Sl. No. Name of the materials Name of the supplier
1 Dextromethorphan HBr Divi’s laboratory.
2 Amberlite IRP 64 Rohm & Haas.
3 Cyclodextrin Roquette.
4 Magnesium trisilicate SPI Pharma Inc.
5 Mannitol(Mannozem EZ) SPI Pharma Inc.
6 Crosspovidone(Polyplasdone XL) ISP Technologies Inc.
7 Sodium starch glycolate DMV International.
8 Croscarmelose sodium DMV International.
9 PharmaburstTM SPI Pharma Inc.
10 Sucralose Alkem laboratories
11 Monoammoniumglycirryzinate Chemiloids.
12 Spermint  flavor Wild
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13 SSF(Lubripharm) SPI Pharma Inc.
PREFORMULATION STUDIES
Preformulation testing is an investigation of physical and chemical properties
of a drug substance alone and when combined with excipients. It is the first step in
the rational development of dosage forms.
Preformulation  investigations  are  designed  to  identify  those  physicochemical
properties  and  excipients  that  may  influence  the  formulation  design,  method  of
manufacture, and pharmacokinetic-biopharmaceutical properties of the resulting product.
Followings are the test performed for the preformulation study.
1. Organoleptic characteristics
2. Physico mechanical characterization
3. Particle size distribution  
4. Moisture content 
5. Compatibility study 
1. Organoleptic Characteristic:
 The color, odor, and taste of the drug were characterized and recorded using descriptive
terminology.
2. Physico-mechanical characterization: 
a) Density measurement:
Bulk Density: It refers to packing of particles. Bulk density is used to determine the
amount of drug that occupies the volume in mg/ml. 
Procedure: Weighed quantity of API was transferred into 100 ml measuring cylinder
without  tapping  during  transfer.  The  volume  occupied  by  drug  was  measured.  Bulk
density was measured by using formula.
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Tapped density:  It  is the ratio of mass of powder to the tapped volume. Tapped
volume is the volume  occupied by the same mass of powder after a standard tapping of a
measure.
Procedure: Weighed quantity of drug was taken into a graduated cylinder. Volume
occupied by the drug was noted down.  Then the cylinder  was subjected to 500, 750
&1250 taps in tap density tester (Electro Lab USP II). According to USP, the blend was
subjected  for  500  taps.  The  %  volume  variation  was  calculated  and  subjected  for
additional 750 taps. The % variation is calculated.
b) Flow properties:
Carr’s Index (Compressibility): The Carr’s index and Hausner’s ratio are measures of
the propensity of powder to be compressed. The packing ability of drug was evaluated
from change  in  volume,  which is  due  to  rearrangement  of  packing  occurring  during
tapping. It is indicated as Carr’s compressibility index and is calculated as follows.
Carr’s index = [Tapped density - Bulk density/Tapped density] X 100
Hausner’s  ratio:  It  is  measurement  of  frictional  resistance  of  the  drug  .It  is  the
determined by the ratio of tapped density and bulk density
Hausner’s ratio = Tapped density / Bulk density
Table-8: Interpretation of Powder Flow
% Compressibility Index Flow Character Hausner Ratio
< 10 Excellent 1.00–1.11
11–15 Good 1.12–1.18
16–20 Fair 1.19–1.25
21–25 Passable 1.26–1.34
26–31 Poor 1.35–1.45
32–37 Very poor 1.46–1.59
>38 Very, very poor >1.60
Angle of Repose (AOR):
It is defined as the maximum angle that can be obtained between the free standing of
powder heap and horizontal plane, which is given by the equation:
                                             θ = tan-1 h/r
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Where   θ   = Angle of repose
              h   = Height of the pile
              r   = Radius of the base of the conical pile
Procedure: Weighed quantity of the drug was passed through a funnel fixed at a height
of 2 cm from the base. The powder is passed till it forms a heap and touches the tip of the
funnel. The radius was measured and AOR was calculated by using above formula.
3. Particle size distributions:
For  many  active  substances,  particle  size  has  an  impact  on  powder  flow,  content
uniformity and drug dissolution.  In order to assure consistent product quality, the particle
size  of  the  API  has  been  characterised.  Electromagnetic  sieve  shaker  was  used  to
determine the particle size of API and drug resin complex.
4. Moisture content: 
The substance to be tested was mixed and accurately weighed,  and, unless  otherwise
directed in the individual monograph, the moisture content was determined on 1 to 2 g. If
the test specimen is in the form of large crystals, the particle size should be reduced to
about 2 mm by quickly crushing. A clean aluminium pan was taken and placed upon the
pan holder and tared. The accurate amount of the material to be analyzed was taken and
spread on the plate in such a way that a thin layer of uniform thickness is formed. The
analysis specifications were set and test was performed for specified time.
5. Drug-Excipients Compatibility Study:
     Protocol for drug-excipients compatibility:
      (a) Drug: Excipients Ratio
Drug and excipients were taken in the ratios as mentioned in following Table No. 9.
For formulations containing complex of drug and complexing agents or adsorbate of
drug and adsorbents, drug excipients compatibility study was carried out taking drug
complex/adsorbate and excipients ratio.
      (b) Pack details
      Clear transparent glass vials with rubber stopper and aluminum seal and polybags.
      (c) Storage condition
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1. Initial sample at room temperature 
2. Polybags at 40°C/75 % RH for 4 weeks
3. Glass vials at 60ºC for 15 days.
       (d) Test to be performed: Physical observation.
        Procedure: Drug  rein  complex  and  excipients  were  thoroughly  mixed  in
predetermined ratio given in Table No. 9 and passed through the sieve no. 60. The blends
were filled in self sealable polybags and colorless transparent glass vials closed with gray
rubber stoppers sealed with aluminum seal and charged in to condition at 40°C/75 % RH
for 4 weeks and 60°C for 15 days respectively. Similarly API was also subjected to same
conditions and time periods as that of sample.
Table-9: Drug-Excipients Compatibility Study & initial physical observations
Name of Sample % weight Ratio Observation
Dextromethorphan HBr 100:0 White crystalline powder.
Drug resin complex 100:0 Slight off white powder, free flowing. No
aggregates
DRC+ Mannitol 50:50 White powder, free flowing. No aggregates
DRC+ PharmaburstTM 30:70 White powder, free flowing. No aggregates
DRC+ Crospovidone
XL
95:5 Slight off White powder, free flowing. No
aggregates
DRC+ Croscarmellose
Sodium
95:5 Slight off White powder, free flowing. No
aggregates
DRC+ Sodium starch
glycolate
95:5 White powder, free flowing. No aggregates
DRC+ Sucralose 99:1 White powder, free flowing. No aggregates
DRC+ MAG 99:1 White powder, free flowing. No aggregates
DRC+ Spearmint 95:5 White powder, free flowing. No aggregates
DRC+ Citric acid 95:5 White powder, free flowing. No aggregates
DRC+ Magnesium
Trisilicate
15:85 White powder, free flowing. No aggregates
DRC+ SSF 97:3 White powder, free flowing. No aggregates
  Physical observation: Physical observation of each sample was carried out every
week, for any color change or lumps or color formation and flow. 
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TASTE MASKING OF API
Taste-Masking Using Ion-Exchange Resins:
Procedure for taste-masking:
Method I: 
Accurate quantity of resin was weighed and shifted it through sieve no. 60. Little
amount of purified water (HPLC grade) was added and a paste was made using mortar
and pestle by kneading for specified time. Required amount of drug in small quantities
was added gradually and continuing kneading for specified time and the paste was dried
at 60º C for 2 hours.
Method II:
 Required  quantity  of  purified  water  was  taken  and  ion-exchange  resin  was
gradually added to it,  under the continuous stirring condition. Allow it to soak for 30
minutes under continuous stirring (500 RPM). Dextromethorphan HBr was added  in
bulk and keept it under stirring condition for 3 hours. pH was adjusted to desired level if
required.  After  stirring  for  specified  time  the  drug  resin  complex  was  collected  by
vacuum filtration using Whatman filter paper 41 and the resinate was dried at 60ºC. This
drug-resin mixture was used for further study of assay and taste evaluation. The taste
evaluation  was  done  by  volunteers  and  recorded  using  descriptive  terminology.  The
results of drug ion-exchange resin complexation have been shown in Table No. 23.
Taste masking using β-Cyclodextrin:
Procedure for taste masking:
 Method I (Physical mixture): Accurately weighed drug and cyclodextrin was
taken in a poly bag and mixed for 30 minutes.
 Method  II (Kneading):  Accurate  quantity  of  cyclodextrin  was  weighed  and
shifted it through sieve no 60. Little amount of purified water (HPLC grade) was
added and a paste was made using mortar and pestle by kneading for specified
time.  Required  amount  of  drug  in  small  quantities  was  gradually  added  and
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continuing kneading for specified time and the paste was dried at  45º C for 2
hours. The results of drug-cyclodextrin complexation have been shown in Table
No. 24
Taste masking using Magnesium trisilicate:
 Method I (Kneading): Accurate quantity of magnesium trisilicate was weighed
and shifted through sieve no 40. Little amount of purified water (HPLC grade)
was  added  and  a  paste  was  made  using  mortar  and  pestle  by  kneading  for
specified  time.  Required  amount  of  drug  in  small  quantity  was  added  and
continuing kneading for some time and dried the paste at 60º C for 2 hours. The
results of drug-magnesium trisilicate complexation have been shown in Table No.
25.
 Method II ((Kneading): Required amount of magnesium trisilicate was taken in
a mortar and dissolved in small amount of water at 70-80o  C. The drug solution
was added to the magnesium trisilicate and kneaded for specified time and dried
at 60oC for 2 hours.
Detection of copmplexation by Differential Scanning Calorimetry:
The DSC thermograms of successfully taste masked drug complex were recorded on a
Metller Toledo DSC-60. Samples of drug complex of 2 mg were heated in hermetically
sealed aluminum pans over a temperature range of 50o C to 200o C at a constant rate of 5o
C/ minute under nitrogen purge. The results of DSC studies have been shown in Figure
No. 12-16.
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FORMULATION OF ORALLY DISINTEGRATING TABLET
Selection of Excipients:
The excipients were selected from the drug excipient compatibility study and used in the
final formula within the limit of inactive ingredient guide available by FDA.
Selection of flavoring agent:
In the preparation of orally disintegrating tablets, taste and flavor is considered as
the most essential criteria. To attain good palatability, flavoring agents are added to the
formulation. Two flavoring agent; spearmint flavor and cherry flavor were selected and
incorporated  in  the  placebo  blend.  Placebo  tablets  were  compressed  by  direct
compression using 9.5mm FFBE and evaluated for taste and mouth feel. To observe taste
and mouth feel 10 volunteers were selected and their comments were recorded in Table
No. 18 according to the descriptive terminology tabulated in Table No. 10. 
Optimization  of  Flavoring  Agent  for  Pleasant  Mouth  Feel:  Optimization  of
concentration of selected flavoring agent was done by incorporating 0.5%, 1%, 1.5% w/w
concentration of selected flavoring agent and compressing placebo tablets using same
tooling. To observe the taste and mouth feel 10 volunteers were selected and results have
been tabulated in Table No 19.
Table - 10: Flavor selection and optimization scale
Remarks Ratings
Bad B
Average A
Good G
Excellent E
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PROCEDURE FOR PREPARATION OF TABLETS:
Step 1: Dispensing
Required quantity of Dextromethorphan HBr and other excipients were accurately
weighed, according to the trial formulation.
Step 2: Shifting
 Diluent and disintegrants were passed through # 40 mesh, drug resin complex, flavor,
and lubricant were passed through # 60 mesh, either alone or in combination with other
excipients.
Step 3: Mixing/Blending:
The blend of drug resin complex and other excipients were blended well using a double
cone blender at 100 rpm for 10 min.
Step 4: Direct compression:
Orally disintegrating tablets were prepared by direct compression of the prepared
blend using 9.5 mm FFBE punches at a Rimek Minipress 8 station single rotary tablet
compression machine. 
EVALUATION OF COMPRESSED TABLETS:
All  the  tablets  were  evaluated  for  different  parameters  as  appearance,  uniformity  of
weight,  thickness,  hardness,  friability,  in-vitro  disintegration  time,  assay  and  in-vitro
dissolution study. 
 Appearance: 
The general  appearance and elegance of tablet  was identified visually,  which include
tablet color, shape, surface texture.
Uniformity of weight: Twenty tablets were weighed individually and collectively and
then average weight was determined. The individual tablet weight was compared with
average tablet weight. 
Thickness, diameter and hardness:
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Tablets were selected at random from individual formulations and thickness, diameter
and  hardness  were  measured  by  using  Schleuninger  tablet  tester  instrument  which
permits accurate measurement of these parameters.
Friability:
Friability  is  related  to  tablet’s  ability  to  withstand  both shocks and  abrasion  without
crumbling  during  manufacturing,  packing,  transportation  and  consumer  handling.
Friability can be evaluated by means of Roche type friability test apparatus. Compressed
tablets that loose less than 1.0% in weight are generally considered acceptable.
Method: Tablets  were  weighed  accurately  (initial  wt.),  transfer  into  friabilator  and
subjected  to  100  revolutions  in  4  minutes.  The  tablets  are  collected,  dedusted  and
reweighed (final wt). These two weights were applied to following formula and friability
was calculated.
     
(Initial Weight – final weight)
                 % Friability      =    ---------------------------------------    x 100
      (Initial weight) 
 Disintegration test: 
The  disintegration  time  was  measured  by  using  USP disintegration  test  apparatus.  6
tablets  were  placed  in  tubes  and  the  basket  is  kept  positioned  in  a  1-litre  beaker
containing 800 ml of water maintained at 37±2oC. The tablet remain 2.5 cm from the
bottom of water, a standard motor driven device move the basket containing tablet up and
down through a distance of 5 to 6 cm at a frequency of 28 to 32 cycles per minute. The
time taken for complete disappearance of each tablet was recorded. 
Dissolution  study: The  release  rate  of  Dextromethorphan  Hydrobromide  from orally
disintegrating tablets was determined using USP dissolution testing apparatus II (paddle
type). The dissolution test was performed using 900 ml of 0.1N HCl at 37±0.5oC and 50
rpm. 
Taste and mouth feel evaluation:
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 Taste and mouth feel evaluation was performed by in vivo disintegration on 10 healthy
human volunteers. One tablet was held in the mouth after rinsing and the time required
for complete disintegration of the tablet  was recorded. The disintegrsted material  was
held in the mouth for another 60 seconds and spat out. The mouth was rinsed with water
without  swallowing  the  disintegrated  material  and  finally  the  roughness  levels  were
recorded on a numerical scale ranging from 0 to 5, where 0,1,2,3,4,5 indicate bitter, bitter
after, no bitter, pleasant, pleasant taste and good mouth feel, pleasant taste and excellent
mouth feel. An adequate time interval was maintained between each evaluation to avoid
confusion.
Table-11: Taste and Mouth Feel Evaluation Scale
TASTE RATING
Bitter 0
Less Bitter 1
No Bitter Taste 2
Pleasant taste 3
Pleasant taste & Good
Mouth Feel
4
Pleasant taste &
excellent Mouth Feel
5
Selection of Optimized Formulation:
The optimized formulation of Dextromethorphan ODT was selected from the formulation
trials and on the basis of Taste, assay, disintegration time, physical appearance of tablets, 
and in vitro dissolution study
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STABILITY STUDY:
Stability testing of drug products begins as a part of formulation development and
ends with the demise of the compound or commercial product. FDA and ICH specifies
the guidelines for stability testing of new drug products, as a technical requirement for
the registration of pharmaceuticals for human use.
The ICH Guidelines have established that long term stability testing should be
done at 25oC/60% RH; stress testing should be done at 40oC/75%RH for 6 months. If
significant change occurs at these stress condition, then the formulation should be tested
at an intermediate condition i.e. 30oC/75%RH. Table shows different temperatures and
period of stability testing. 
Table-12: ICH guide lines for storage conditions and time period stability study
Study Storage condition Time period
Long term
25°c±2°C/60%± RH5%RH or
30°c±2°C/65%RH±5% RH
12 month
Intermediate 30°c±2°c/65% ±RH5% RH 6 month
Accelerated 40°c±2°c/75%± RH5% RH 6 month
In  the present work stability study was carried  out for  the optimized formulation for
following packaging, condition and time period.
• 40°C±2°C/75% RH±5% RH in HDPE bottles and PVC PVDC 60 GSM blisters.
.
76
RESULTS AND DISCUSSIONS
Pre-formulation studies: 
Table-13: Organoleptic Characteristics of Dextromethorphan HBr
Properties Results
Color White to off white
Taste Very bitter
Odor Odorless
Table-14: Particle size distribution of Dextromethorphan HBr
Particle size(µ) %w/w
600 2.4
420 1.2
250 26
177 3.6
149 9.2
<149 58.8
Table-15: Bulk Properties of Dextromethorphan HBr
S. No Parameters Results
1 Bulk Density 0.4
2 TappDensity 0.57
3 Carr’s index 29.82
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4 Hausner’s ratio 1.42
5 Angle of repose 30.3
The physico mechanical properties of the drug such as particle size distribution, angle of
repose, bulk density and tapped density, compressibility index (CI), and Hausner’s Ratio
were determined. The results are presented in the Table no.14 and 15. Since 58.8% w/w
of API contains particles of size <149µ, the ODTs prepared by direct compression will
show good content uniformity.  The CI and angle of repose of Dextromethorphan was
found to be 29.82 and 30.3 indicating that the drug has poor flow properties and poor
compressibility.  Since  the drug is  to  be used  as  the resinate  in  final  formulation the
physico mechanical propreties of resinate is also to be determined.
Table-16: Taste Masking Trials by Ion Exchange resin
B.NO TM1 TM 2 TM 3 TM 4 TM 5 TM 6 TM 7 TM 8
Drug:A.IPR64 1:1 1:2 1:3 1:3 1:3 1:2 1:3 1:3
Method Slurry Slurry Slurry Slurry Slurry Slurry Slurry Wet
mass
Soaking
time(min) 30 30 30 60 30 30 30 ---
pH Adjustment NA NA 6.5 6.5 8.0 8.0 8.0 ---
Stirring
time(hr) 1 1 2 2 2 2 4 ---
Kneading
time(min) --- --- --- --- --- --- --- 30
Drying time at
60°C(hrs) 2 2 2 2 2 2 2 2
Taste Bitter Bitter LessBitter
Less
Bitter
Taste
less
Less
bitter
Taste
less Bitter
%Drug in
Resinate 10.24 14.84 19.82 19.84 22.8 17.7 22.78 NA
Result & Discussion: As presented in above table the resinate of B.No. TM1, TM2 and
TM8 were found as bitter. Comparatively less bitter resinates were obtained from B.No
TM3, TM4 and TM6, but complete taste masking was not achieved. Resinate of B.No
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TM5and  TM7  was  found  to  be  completely  taste  masked.  The  results  completely
demonstrated that efficient taste masking as well as high drug loading was achieved with
subsequent increase in the amount of resin in drug: resin ratio and pH of the complexing
medium. At higher amount of resin and higher pH, maximum dissociation of –COOH
group of the resin  takes place and subsequently the number of sites for drug binding
increases. Soaking process was fixed to 30 minutes and the complexation process was
fixed to 2 hour as the drug loading showed no significant change. So B.No. TM5 was
selected as the optimum process for taste masking by ion-exchange resin. 
Table-17: Taste Masking Trials By β Cyclodextrin
 
B.No TM 9 TM 10 TM 11 TM 12
Drug: CD 1:5 1:5 1:5 1:10
Method Physical mixture Kneading Kneading Kneading
Kneading time 30 min 30 min 60 min 60 min
Water --- q. s q. s q. s
BitterBitterLess
bitterDrying time at
45°C(hour)
2 2 2 2
Bitter
Taste
Result & Discussion: Only the B. No TM12 shows some extent of taste masking but it
was not taste less. Bitter after taste was felt. Other trials do not show any taste masking.
Table-18: Taste Masking Trials by Magnesium trisilicate
B.No TM13 TM14 TM 15 TM16
Drug: MTS 1:5 1:5 1:5 1:7.7
Method Kneading Kneading Kneading Kneading
Kneading time 30 min 30 min 60 min 60 min
Medium Cold
water Hot water Hot water Hot water
Drying time at
60°C (Hour) 2 2 2 2
Taste Bitter Bitter Bitter Less bitter
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Result & Discussion: Only the B. No TM 16 shows some extent of taste masking but it
was not completely taste less. Less bitter taste was felt. Other trials do not show any taste
masking.
Detection of complexation:
DSC study of Drug resin complexation:
DSC thermogram of Dextromethorphan HBr API, Amberlite IRP64, drug resin complex
prepared at pH6, pH8, and pH10 has been shown in Figure No. 8-12 respectively. DSC
thermogram  showed  a  sharp  endothermic  peak  at  117.55oC.  DSC  thermogram  of
Amberlite  IRP64 showed a broad  endothermic peak between  25.56oC- 99.55oC. DSC
thermogram  of  drug  resin  complex  prepared  at  pH6  and  pH8  showed  a  broad
endothermic  peak  between  74.29 oC-102.32 oC  and  47.42 oC  -106.63 oC  indicating
formation of complex. But DSC thermogram of drug resin complex prepared at pH10
showed a broad endothermic peak  at 92.48 oC and a sharp endothermic peak at 109.75 oC
indicating poor complexation.
Fig-12: Thermal analysis report of Dextromethorphan HBr API.
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Fig-13: Thermal analysis report of Amberlite IRP64:
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Fig-14: Thermal Analysis report of Dextromethorphan HBr- IRP64 complex at pH6
Fig-15: Thermal Analysis report of Dextromethorphan HBr-IRP64 complex at pH 8
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Fig-16:Thermal Analysis report of Dextromethorphan HBr-IRP64 complex at pH10
Physico-mechanical characterization of Drug resin complex:
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Table-19: Particle size distribution of Dextromethorphan HBr resinate
Particle size(µ) %w/w
420 6
250 8
177 2
149 5
<149 79
Table-20: Bulk Properties of Dextromethorphan HBr resinate
S. No Parameters Results
1 Bulk Density 0.47
2 Tapped Density 0.65
3 Carr’s index 27
4 Hausner’s Ratio 1.39
5 Angle of Repose 28.3
Result and discussion:  The physico mechanical  properties of the drug-resin complex
such  as  particle  size  distribution,  angle  of  repose,  bulk  density  and  tapped  density,
compressibility  index  (CI),  and  Hausner’s  Ratio  were  determined.  The  results  are
presented in the Table No.19 and 20 respectively.. The CI and angle of repose of drug-
resin  complex  was  found  to  be  27  and  28.3  indicating  that  the  drug  has  poor  flow
properties  and  poor  compressibility.  So  the  diluent  for  the  tablet  formulation  to  be
prepared by direct compression should have a granular structure with good flow property
to exert a good flow of powder blent to be compressed as ODT. A suitable lubricant has
to be selected to over come any manufacturing defect generally caused by poor flow of
powder blend.
Drug-Excipients Compatibility Study:   
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Table-21: Result of Drug-Excipients Compatibility Study & Physical observation
Name of Sample
%
weight
Ratio
Observation
Polybag, 40º C/75% RH Glass vial,60º C
Dextromethorphan HBr 100:0 No change observed No change observed
Drug resin complex 100:0 No change observed No change observed
DRC+ Mannozem EZ 50:50 No change observed No change observed
DRC+ PharmaBurstTM 30:70 No change observed No change observed
DRC+ Crospovidone 95:5 No change observed No change observed
DRC+ Croscarmellose
Sodium 95:5 No change observed No change observed
DRC+ Sodium starch
glycolate 95:5 No change observed No change observed
DRC+ Sucralose 99:1 No change observed No change observed
DRC+ MAG 99:1 No change observed No change observed
DRC+ Spearmint 95:5 No change observed No change observed
DRC+ Magnesium
Trisilicate 15:85 No change observed No change observed
DRC+ SSF 97:3 No change observed No change observed
Result and Discussion: After 4 weeks, the samples were visually observed. No 
incompatibility was found visually at 40oC/75%RH condition in both types of packs. So 
the selected excipients can be used for formulation of orally disintegrating tablets. The 
optimized amount of each excipient is to be selected by different formulation trials and 
the final formulation is to be prepared.
Flavor Selection: The result of the flavor selection study is shown in the table below.
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Table-22:  Result of Flavor Selection
Volunteers Spearmint flavor Cherry flavor
1 E G
2 E E
3 E A
4 G E
5 E E
6 E A
7 G G
8 E E
9 E G
10 E E
Discussion: Eight out of Ten volunteers rated the spearmint flavor as excellent and six
out of ten volunteers rated cherry flavor as good. So mint flavor was selected for final
ODT formulation. 
Fig-8: Graphical representation of flavor preference of volunteers
Table-23: Optimization of Flavoring Agent for Pleasant Mouth Feel:
Volunteers 0.50% 1% 1.50%
1 G E B
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2 A E G
3 G E A
4 A G B
5 G E E
6 G E A
7 E G B
8 A E B
9 G E A
10 A G B
Discussion: As presented in the above table. Five out of ten volunteers selected 0.5% as
good, eight out of ten volunteers selected 1% as excellent and seven out of ten volunteers
rated 1.5% as bad. So the 1% concentration of mint flavor was optimized for final ODT
formulation.
Fig-9: Optimization of concentration of flavoring agents
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B. No F1 F2 F 3 F 4 F 5 F 6 F 7 F 8 F 9 F 10 F 11 F 12
Ingredients Quantity/ Tablet
DRC 43.85 43.85 43.85 43.85 -----
D-CD complex ----- ---- ---- ---- 110 110 110 110
D-MTS adsorbate ---- ----- ---- ---- ----- ----- ----- ----- 87 87 87 87
Mannogem EZ 234.55 234.55 234.55 ---- 168.4 168.4 168.4 ----- 191.4 191.4 191.4 ----
Crospovidone XL 12 ----- ----- ----- 12 ---- ---- ---- 12 ---- ---- ----
Croscarmellose
Sodium ---- 12 ----- ----- ----- 12 ---- ---- ---- 12 ---- ----
Sodium Starch
Glycolate ---- ----- 12 ----- ----- 12 ---- ---- 12 ----
Pharmaburst TM ---- ---- ---- 246.55 ---- ---- ---- 180.4 ---- ---- ---- 203.4
Sucralose 3 3 3 3 3 3 3 3 3 3 3 3
MAG 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6
Spearmint Flavor 3 3 3 3 3 3 3 3 3 3 3 3
SSF 3 3 3 3 3 3 3 3 3 3 3 3
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Table-24: Formulation of Dextromethorphan HBr ODT.
Total weight of each tablet is 300 mg.
Taken amounts of DRC, D-CD complex and D-MTS adsorbate contain 10 mg Dextromethorphan HBr.
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Table-25: Evaluation of Dextromethorphan HBr ODT formulations
B. No F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12
Average 
Weight 300.48±1.01
300.66±
1.12
300.34±
1
300.1±0.
92
299.61±
1.1
299.52±
1.03
299.89±
0.94
300.1±1.
08
300.9±1.
2
299.83±
1.14
300.5±1.0
9
301.6±1.
01
Thickness 3.67±0.06 3.67±0.03
3.67±0.0
1
3.64±0.0
1
3.68±0.0
3 3.62±0.2 3.6±0.01
3.64±0.0
8
3.65±0.0
6 3.61±0.5 3.62±0.01 3.63±0.1
Diameter 9.56±0.03 9.58±0.08 9.57±0.1
9.61±0.1
5 9.6±0.93
9.71±0.6
8
9.67±0.3
9
9.62±0.1
2 9.56±0.1
9.62±0.3
8 9.61±0.46
9.58±0.8
5
Hardness 5.3±0.01 5.2±0.05 5.2±0.8 5.4±0.4 5.5±0.1 5.4±0.17 5.4±0.31 5.32±0.28 5.2±0.1 5.2±0.09 5.3±0.5 5.2±0.41
DT(sec) 22 35 42 19 30 58 70 28 21 33 38 22
%Friability 0.17 0.47 0.92 0.24 0.26 0.18 0.2 0.25 0.22 0.21 0.18 0.23
AOR 21.8 22.11 22.89 20.46 42.56 42.6 44 36.5 23.1 22.53 22.0 21.5
B.D 0.46 0.51 0.48 0.44 0.26 0.31 0.28 0.3 0.42 0.44 0.43 0.42
T.D 0.50 0.56 0.53 0.48 0.35 0.42 0.36 0.39 0.49 0.50 0.50 0.46
C.Index 8.37 8.92 9.43 8.33 25.71 26.19 22.22 23.07 14.28 12.0 14.0 8.7
H. Ratio 1.08 1.09 1.10 1.09 1.34 1.54 1.28 1.3 1.16 1.13 1.16 1.09
LOD 2.87 2.31 2.38 2.68 4.88 4.78 5.01 4.94 2.53 2.61 2.38 2.41
%Assay 101.56 103.25 102.65 102.41 98.78 101.2 100.7 99.84 104.3 101.2 100.5 102.6
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Result and Discussion:
 Tablets from each batch showed good uniformity of weight, thickness, diameter,
ranges from 299.52 -301.6 mg, 3.61mm-3.68 mm and 9.56 mm-9.71 mm respectively.
Sufficient hardness ranges from 5.2-5.4 Kp was maintained uniformly through out the
different formulation batches with percent friability less than 1%.
The results of angle of repose, bulk density,  tapped density,  compressibility indes and
Hausner ratio showed good flow property compressibility of tablet blends except batch
no. from F5-F8. The unsatisfactory physico mechanical properties of these batches (F5-
F8)  may  be  due  to  the  presence  of  cyclodextrin  which  has  a  poor  flow  and
compressibility in direct compression.
Tablets  containing  crospovidone  as  superdisintegrant  showed  quick
disintegration  followed  by  croscarmellose  sodium  and  sodium  starch  glycolate.  The
probable reason for delayed disintegration of the tablets with croscarmelose sodium and
sodium starch glycolate might be due to their tendency form a gel like consistency. The
faster disintegration of formulations containing crospovidone is due to its rapid water
uptake  by  wicking  from  the  medium,  swelling  and  burst  effect.  Tablets  containing
crospovidone seems to swell immediately despite the limited swelling capacity of this
class of superdisintegrants. Crospovidone exhibits a high capacity to retain deformation
during postcompression. The rapid swelling of these tablets upon wetting may partly be
attributed to the recovery of deformation. 
Tablets  containing  PharmaburstTM quick  dissolving  system  exhibit  faster
disintegration  than  tablets  containing  crospovidone.  This  may  be  explained  by  the
presence of mannitol. Prsence of higher amount of polyols increase the wetting time and
subsequently disintegration time increases. As mannitol is readily soluble in water, there
exists a competition between mannitol and crospovidone for water penetration into the
tablets, consequently leading to poor swelling of crospovidone with subsequent delay in
Table-26: Taste evaluation of Dextromethorphan HBr ODT
Volunteers
B. No
V1 V 2 V 3 V 4 V 5 V 6 V 7 V 8 V 9 V 10
F1 5 5 4 5 4 5 5 5 5 5
F2 4 4 3 4 3 4 4 3 4 3
F3 4 4 3 3 3 3 4 3 3 3
F4 5 5 5 5 4 5 5 5 5 5
F5 1 1 1 1 1 1 1 1 0 1
F6 0 1 0 1 1 1 1 1 1 0
F7 1 0 1 1 0 0 1 1 0 0
F8 1 1 1 1 1 1 1 1 1 1
F9 0 0 0 1 0 0 0 0 0 0
F10 0 0 0 0 0 0 0 0 0 0
F11 0 0 0 0 0 0 0 0 0 0
F12 1 0 0 0 0 0 0 0 0 0

In-vitro Drug Release Study:
Table-27: In vitro release of Dextromethorphan HBr from ODT formulations.
Time
(minutes) F1 F2 F3 F4
0 0 0 0 0
3 40.34±0.1 35.63±0.92 33.87±1.06 45.73±0.05
6 72.16±0.34 52.58±0.14 51.22±0.92 77.52±0.02
9 97.84±0.17 70.93±0.24 67.39±0.5 96.94±0.09
12 100.09±0.2 90.68±0.2 74.66±0.64 100.91±0.1
15 101.12±0.16 94.83±0.35 83.64±0.96 101.28±0.14
30 101.29±0.31 100.52±0.72 91.84±0.83 101.59±0.21
45 101.34±0.2 101.89±0.83 101.86±0.78 102.12±0.04
Fig-11: Dissolution profile of Dextromethorphan ODT
Discussion: Formulation of B.No. F1 and F4 showed very good immediate drug release
in compare to F2 and F4. More than 95% drug release was achieved with in 9 minute.
In the  present  work  our  aim  was  to  develop  such  a  formulation  which  shows  less
disintegration  time,  good  taste  and  mouth  feel  and  immediate  drug  release  profile.
Considering all the parameters, formulations of B.No. F1 and F4 have been found to be
the best formulations with all respect.
Table-28: Final Optimized Formulation of Dextromethorphan ODT
 Total
weight  of each  tablet
is 300 mg.
Table-29: Inactive
ingredient potency of
selected excipients
Name of the excipients Maximum allowable daily intake (mg)
[CDER, US FDA- IIG Limit]
Mannitol 221.00
Crospovidone 15.00
Croscarmellose sodium 13.00
Sodium starch glycolate 71.43
B. No. F1 F4
Ingredients Quantity/ Tablet
DRC 43.85 43.85
Mannitol 234.55 --
Crospovidone 12 --
Pharmaburst TM 246.55
Sucralose 3 3
MAG 0.6 0.6
Spearmint flavor 3 3
SSF 3 3
STBILITY STUDY:
The finally optimized formulations of B.No. F1 and F4 were kept for stability study at
40o C/75% RH. Different physical parameters, assay and in vitro drug release study were
carried out after one month. The results after one month stability period are shown in the
table.
Table-35: Observations of 1 month Stability Study
Evaluation
Pack details and condition
40°C/75 % RH (1 Month)
Average
Weight
(mg)
300.48±1.01 300.1±0.92 300.94±1.1 300.20±1.06 300.5±1.14 300.28±1.12
Thickness
(mm) 3.67±0.04 3.64±0.06 3.7±0.11 3.66±0.07 3.68±0.3 3.64±0.23
Diameter 9.56±.03 9.61±0.05 9.6±0.04 9.63±0.02 9.58±0.06 9.60±0.08
Hardness
(Kp) 5.3±0.16 5.5±0.11 5.1±0.2 5.4.±0.18 5.5±0.26 5.8±0.31
Friability
(%)
0.17 0.24 0.2 0.27 0.1 0.18
D. T. (sec) 22 19 20 20 22 21
Assay (%) 101.7 102.41 101.53 102.0 101.65 101.94
Taste
evaluation
5 5 5 5 5 5
Each value of average weight, thickness, diameter and hardness is mean± SD
In vitro drug release study of 1 month stability sample: Samples of Dextromethorphan
HBr ODT of each type of pack were withdrawn after one month and in vitro drug release
study was carried out using same method used for initial samples.
Table-36: In vitro drug release after 1 month stability study
    Each value is mean±SD
Fig-17: Dissolution profile of 1 month stability sample of Dextromethorphan HBr
ODT
Time
% Drug release ± SD
F1 F4
PVC PVDC
60 GSM
HDPE PVC PVDC
60 GSM
HDPE
0 0 0 0 0
3 42.84±1.24 32.22±0.1 45.14±1.2 36.37±0.4
6 75.25±1.16 70.3±0.53 77.76±0.9 72.87±0.16
9 99.52±0.9 95.3±0.63 97.17±1.1 95.47±0.25
12 100.1±1.04 99.97±0.2 100.45±0.87 100.04±0.14
15 101.28±0.22 101.07±0.42 101.72±1.16 100.43±0.11
30 101.43±0.12 101.4±0.35 101.78±1.22 100.82±0.31
45 101.5±0.54 101.43±0.15 102±1.52 101.26±0.46
Result  and  discussion:  No  observed  change  was  found  in  the  tablet  evaluation
parameters  in  both  types  of  packagings.  In  vitro  drug  release  study also  showed no
observed change when compared with the initial release. 
SUMMARY AND CONCLUSION
 The  present  study  was  carried  out  to  develop  a  solid  oral  dosage  form  of
Dextromethorphan HBr in the form of orally disintegrating tablet having pleasant
taste and mouth feel that disintegrate within few seconds upon placing on tongue.
 Since  Dextromethorphan HBr is  extremely bitter,  different  techniques of  taste
masking  were  applied  to  reduce  bitterness  of  drug  and  to  get  palatable
formulation.  The  techniques  used  were  ion-exchange  resin  complexation  with
Amberlite  IRP64,  inclusion  complexation  using  β  cyclodextrin  and  adsorbate
formation with magnesium trisilicate and ion exchange resin complexation which
is simplest, efficient and cost effective is selected for further work.
 In  present  study,  it  is  found  that  Amberllite  IRP  64  can  mask  bitter  taste  of
Dextromethorphan HBr by complex formation.
 Maximum drug loading is achieved using Amberlite IRP 64 and immediate drug
release is achieved during dissolution study.
 DSC study shows complete complexation of Dextromethorphan- Amberlite IRP
64 complex prepared maintaining the pH of complexing medium at 8.
 Tablets  prepared  by  direct  compression  are  visually  attractive,  possess  good
mechanical strength with sufficient hardness.
 Targeted  invitro  disintegration  time  is  achieved  by  using  crospovidone  as  a
superdisintegrant.
 Spray dried mannitol of  SPI Pharma (Mannozem EZ) provides very good flow of
the  powder  blend  and  excellent  smooth  mouthfeel  has  been  experienced  by
volunteers. Mannitol contributes to the good taste of the formulation due to it’s
cooling sensation in mouth.
 The  mouth  feel  of  the  prepared  formulation  can  be  compared  with  the
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